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Abstract 
The RND superfamily of efflux pumps plays vital roles in the intrinsic defense mechanisms of 
bacterial pathogens. The Staphylococci have two genes encoding RND efflux pumps; farE, which 
promotes efflux of antimicrobial fatty acids, and an uncharacterized gene we have named femT. 
Although RND pumps are known to play roles in physiological function and antimicrobial 
resistance, the function of FemT, and the relationship between FemT and FarE in Staphylococci 
have not been identified. Using established assays, we have tested the phenotype of a femT deletion 
mutant. Here, we show that this mutant is more susceptible to lysostaphin, vancomycin and 
oxacillin, and grows faster in Mueller-Hinton broth. Most notably, when evaluating the 
relationship between these transporters, inducible expression of FarE in fatty acids was abolished 
in FemT-deficient mutants. These findings suggest an interplay between the two transporters, and 
cumulatively, represent the first description of both systems operating in S. aureus.  
 
Keywords: Staphylococci, USA300, MRSA, RND protein, redundancy, efflux pumps, 
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1.1 Overview of Staphylococcus aureus 
1.1.1 Background 
Staphylococci are Gram positive, spherical bacteria that are distinguished microscopically by their 
characteristic organization into clusters. The Staphylococcus genus includes at least 40 species, 
most of which are harmless and reside normally on the skin and mucous membranes of humans 
and other organisms. Although members of the staphylococci are commensal, benign colonization 
can be the starting point for disease, transmission, and selection of new microbial traits. Therefore, 
bacteria in this category can be identified as pathobionts, as they exhibit duality of behavior from 
commensal to pathogen (1). This is especially true for the most pathogenic of the staphylococci, 
Staphylococcus aureus.  
Carriage of S. aureus as a commensal appears to play a significant role in the epidemiology and 
pathogenesis of infection. As part of the normal flora, S. aureus asymptomatically colonizes skin 
and mucous membranes, with the anterior nares being the most consistent area from which this 
organism can be isolated (2). Over time, three patterns of carriage can be distinguished: roughly 
20% of people are persistent carriers, 60% are intermittent carriers, and approximately 20% almost 
never carry S. aureus (3). Although the presence of S. aureus as a commensal is asymptomatic, 
carriage has been identified as a risk factor for the development of S. aureus infections. 
The identification of S. aureus as a pathogen began with its discovery in 1880 by Scottish surgeon 
Alexander Ogston, who first observed the bacterium while microscopically examining a pus 
sample removed from the leg of a patient (4). Ogston hypothesized that acute abscesses were 
caused by micrococci and, after injecting pus from infected abscesses into healthy animals, could 
demonstrate that new abscesses formed, followed by signs of septicemia and death (5). In 1882, 
what Ogston described as micrococci were named Staphylococcus due to their spherical, cocci 
shape and growth in masses that mimic the appearance of a bunch of grapes (6). Two years later, 
Anton J. Rosenbach coined the term Staphylococcus aureus, from the Latin word ‘aurum’, 
meaning gold, owing to their distinctive gold hue on agar medium (7). The pigment molecule 
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staphyloxanthin has since been attributed to this characteristic gold colour, and is an important 
contributor to the remarkable virulence of S. aureus and its ability to cope with environmental 
stresses by acting as an antioxidant that helps evade death by reactive oxygen species produced by 
the host immune system (8). In addition to its microscopic appearance and production of 
staphyloxanthin, S. aureus can also be distinguished by the production of the major virulence 
factor coagulase, a protein that binds prothrombin and facilitates the conversion of fibrinogen to 
fibrin, causing clot formation in plasma (9). Traditionally, staphylococci were divided into two 
groups based on their ability to produce coagulase, with the coagulase-positive staphylococci 
constituting the most pathogenic species; however, this classification can be misleading as it has 
been discovered that some S. aureus strains are coagulase-negative (10). These characteristics, 
combined with a large arsenal of virulence factors, have made S. aureus capable of causing a wide 
variety of diseases and syndromes. 
1.1.2 Pathogenesis 
The success of S. aureus as a pathogen and its ability to cause such a wide range of infections are 
the result of its extensive virulence factors, and initial exposure of S. aureus to host tissues beyond 
the skin and mucosal surfaces is thought to trigger upregulation of virulence genes (11). Carriage 
of S. aureus provides a reservoir from which bacteria can be introduced when host defenses are 
breached, whether by open wound inoculation, insertion of an indwelling catheter, surgery, or 
viral-mediated damage in the mucosa of the respiratory tract. Therefore, colonization of the skin 
and anterior nares by S. aureus is a common precursor to infection (12). Multiple studies have 
confirmed this finding, with a substantial proportion of S. aureus infections appearing to be of 
endogenous origin, as they originate from the strain present in the nasal mucosa (12, 13). If a host 
is not colonized with S. aureus asymptomatically via carriage as a commensal, colonization with 
S. aureus can occur due to transmission among individuals in health care and community settings.  
When encountering the body surfaces, S. aureus cells first interact with and adhere to epithelial 
surfaces on the skin and mucosa. The presence of adherent bacterial cells is sensed by epithelial 
surface receptors that recognize microbial components derived from the bacterial cell wall, 
including wall teichoic acid, lipoteichoic acid, peptidoglycan, and lipoproteins (15). Once the host-
pathogen interface has been breached and infection is established, S. aureus can cause skin and 
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soft tissue infections, the most common being abscesses. Pyogenic bacterial abscesses can form in 
deeper tissues, such as underlying muscle, and bacteria can disseminate to form abscesses at distal 
sites and affect virtually any internal organ system (16). Abscess formation and tissue invasion is 
mediated by a range of secreted and cell surface factors, such as proteases, lipases, elastases, and 
hemolysins, that enable S. aureus to degrade host cells and tissues, seize nutrients, and spread to 
other sites of the body (17). Regulation of these secreted factors plays a central role in 
pathogenesis, and their expression during the different stages of infection is critical to the success 
of S. aureus as a pathogen (18, 19). In addition to abscess formation, S. aureus can form biofilms 
on host and prosthetic surfaces, enabling the cells to persist via evasion of host defenses and 
antimicrobial molecules (20). S. aureus is also capable of producing septic shock by interacting 
with and activating the host immune system and coagulation pathways. In some S. aureus strains, 
this is due to the production of superantigens, which cause non-specific activation of T-cells 
resulting in polyclonal T cell activation and massive cytokine release (21). Apart from this activity, 
superantigens can also cause symptoms that are characteristic of infection, such as emesis, which 
occurs in cases of food poisoning. In addition to these characteristics, it is now firmly established 
that S. aureus can survive and even replicate both inside and outside many mammalian cell types, 
including macrophages (22, 23). These features represent important strategies by which S. aureus 
circumvents innate immune function to promote bacterial dissemination. 
1.1.3 Cell Wall Biology 
The cell wall of a microorganism is critical for providing protection, support, and shape, but it also 
plays an important role in infectivity and pathogenicity. The cell wall of S. aureus shows the typical 
features of gram-positive bacterial cell walls, composed of a thick layer of peptidoglycan, teichoic 
acids, and wall-associated surface proteins (24). Stress-bearing peptidoglycan is the main 
structural component of the cell wall and acts as a continuous macromolecular cover surrounding 
the cytoplasmic membrane to protect the cell from rupture (25). The two basic structural features 
of this giant macromolecule are linear glycan chains interlinked with short peptide bridges. The 
glycan chains are composed of alternating units of N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc), and the carboxyl group of each MurNAc residue is substituted by 
a short stem peptide subunit. The formation of the three-dimensional structure of peptidoglycan is 
ensured by cross-linking between the peptide subunit of one chain to that of a neighboring chain. 
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It is a distinctive feature of staphylococci that the degree of cross-linking, which is determined as 
a ratio of bridged peptides to the total amount of all peptide ends, is extremely high, on the order 
of 80 to 90%, compared to 50% cross-linking in the walls of bacilli (26–28). 
The characteristic stem peptide branching off the MurNAc unit is synthesized in S. aureus by three 
non-ribosomal peptidyl-transferases; FemX, FemA, and FemB. Using Gly-tRNA as a donor, and 
the peptidoglycan precursor lipid II as a substrate, they add five glycine residues in a sequential 
fashion to form the pentaglycine (Gly5) interpeptide (29). Cross-linking of adjacent peptidoglycan 
strands and anchoring of surface proteins, contributing to the virulence of S. aureus, occurs via 
this Gly5-interpeptide structure (30). An incomplete Gly5 interpeptide leads to aberrant growth, 
requiring compensatory mutations to guarantee survival, while a complete lack is lethal (31–33). 
Importantly, antibiotic resistant S. aureus depend on the correct formation of the peptidoglycan 
precursor, including a complete Gly5 chain, for high-level resistance (34). After transport across 
the cytoplasmic membrane, the peptidoglycan precursor is incorporated into the existing cell wall 
by the penicillin binding proteins (PBPs), which are enzymes that catalyze transglycosylation of 
the sugar moiety and transpeptidation of the Gly5 chain. Since bacterial cell wall synthesis is 
essential to growth, cell division, and maintaining cellular structure, it has been an attractive target 
for antibiotics. For example, β-lactam antibiotics act by inhibiting the synthesis of peptidoglycan, 
specifically by targeting the transpeptidation reaction catalyzed by the PBPs. Synthesis of 
peptidoglycan and the major constituents of the S. aureus cell wall are summarized in Figure 1.1. 
Wall teichoic acids (WTAs) are another component of the staphylococcal cell wall known to 
contribute to cell morphology and division. WTA polymers play numerous, varied roles in the cell 
wall owing to their location, abundance, and polyanionic nature (35). S. aureus mutants lacking 
these polymers exhibit numerous morphological abnormalities, including a non-uniform 
thickening of the peptidoglycan, increased cell size, and defects in septal positioning and number 
(36, 37).  In addition, WTAs and their attached substituents contribute to cell surface charge and 
hydrophobicity, which in turn affects binding of extracellular molecules and plays a role in 
protection. For example, WTA-deficient cells are more susceptible to antimicrobial fatty acids, 
presumably because the hydrophobic fatty acids can penetrate the less hydrophilic mutant cell wall 
more easily, and bind to the cell membrane where they can elicit their antibacterial effects (38). 







Figure 1.1 Overview of peptidoglycan synthesis in S. aureus. The process begins in the 
cytoplasm, where the Lipid II precursor is formed. A peptide crossbridge of five glycine residues 
is added at the third amino acid by the non-ribosomal peptidyl-transferases FemX, FemA, and 
FemB. Lipid II-Gly5 is then flipped to the external side of the cell membrane, where it is 
incorporated into nascent peptidoglycan by penicillin binding proteins (PBPs). PBPs catalyze 
transglycosylation and transpeptidation reactions, resulting in the respective polymerization and 







1.1.4 Emergence of Antibiotic Resistance 
The combination of virulence factors and staggering rates of antibiotic resistance of S. aureus has 
led to its classification of a ‘superbug’. During the Second World War, Fleming’s discovery of 
penicillin was a revolutionary event, providing an effective antibiotic for the treatment of S. aureus 
infections. Penicillin is a member of the β-lactam family, which is a class of broad-spectrum 
antibiotics that prevent cell wall biosynthesis by binding to and inhibiting PBPs. Yet, only a few 
years after its introduction into clinical practice, penicillin resistance was encountered in hospitals 
and, within a decade, had become a significant problem in the community (41). In 1944, Kirby 
was the first to demonstrate that penicillin was inactivated by penicillin-resistant strains of S. 
aureus, and soon after, Bondi and Dietz identified the specific role of the penicillinase enzyme in 
penicillin resistance (42, 43). To overcome penicillin resistance, penicillinase-resistant antibiotics 
were developed, and methicillin was the first to be produced. Methicillin is a narrow-spectrum 
antibiotic also part of the β-lactam family, however, the first methicillin-resistant S. aureus 
(MRSA) were discovered in the same year methicillin reached the market (44). 
Although the basis of methicillin resistance was not identified until more than 20 years later, it 
was known that the resistance mechanism was different from penicillinase, as there was no drug 
inactivation (41). After examining the PBP patterns of methicillin resistant staphylococci, an 
additional PBP was discovered that conferred resistance to methicillin and all available β-lactam 
antibiotics (45). Whereas non-resistant S. aureus normally employ three PBPs, PBPs 1, 2, and 3, 
to catalyze cross-linking of peptidoglycan, MRSA have an additional PBP, named PBP2a, which 
is encoded by mecA and confers resistance to methicillin. The mecA gene is carried by large (32–
60 kb) sections of chromosomally inserted DNA, which has been termed the staphylococcal 
cassette chromosome mec (SCCmec), likely acquired through horizontal gene transfer from 
Staphylococcus epidermidis (46). Although the mechanism of gene acquisition is not known, two 
genes, ccrA and ccrB, present on the SCCmec have been shown to code for recombinase proteins, 
which are responsible for site-specific excision and insertion into the chromosome (47). During 
the onset of MRSA emergence, isolates were largely restricted to hospitals in large urban centres; 
however, throughout the last few decades, there has been a larger spread of MRSA into smaller 
hospitals and even into the community, referred to as healthcare-associated MRSA (HA-MRSA) 
and community-associated MRSA (CA-MRSA), respectively. One of the major strains attributing 
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to the epidemic wave of CA-MRSA in North America is the USA300 clone. Although USA300 
isolates were initially resistant only to β-lactam antibiotics, mediated by mecA, and macrolides, 
mediated by msrA, they have broadened their resistance profiles considerably over the last 5 years. 
This includes additional resistance to clindamycin, due to the acquisition of ermA and ermC, and 
tetracycline, due to the acquisition of tetK and tetM, as well as resistance to mupirocin, 
fluoroquinolones, vancomycin, and, in some cases, to daptomycin (48–51). 
1.1.5 Origins of Strain USA300 
The increasing prevalence of strain USA300 in the community is of special concern to the medical 
establishment. Perhaps the most notable and well-documented epidemic of CA-MRSA has been 
in the United States, and is attributed to the USA300 strain. The name USA300 describes one of 
many MRSA strains identified in the United States through genomic DNA examination of pulsed-
field gel electrophoresis (PFGE) patterns (52). The strain emerged within S. aureus multilocus 
sequence typing (MLST) clonal complex 8, which is the presumptive ancestor of the first MRSA 
strain, and carried SCCmec (53). MRSA PFGE type USA300 differs from its ancestor strain by at 
least 20 genes, a significant number of which are potentially mobile elements (49). The most 
characteristic genes of USA300 are the Panton-Valentine Leukocidin (PVL) genes and the arginine 
catabolic mobile element (ACME).  
Infections caused by USA300 were first noted in a Mississippi state prison in 1999 where 59 
inmates were infected (54). The infections associated with colonization included moderate to 
severe skin and soft tissue infections (SSTIs) and more invasive infections, including necrotizing 
pneumonia, fasciitis, and bone and joint infections. During the next few years after the first 
outbreak, further outbreaks appeared in which infected individuals had no link to healthcare 
systems. These outbreaks occurred among prisoners, children, and athletes. Although there were 
no ascertainable links between the various outbreaks, the PFGE patterns of the isolates recovered 
from all the involved individuals were mostly type USA300 (48). Since then, USA300 has become 
one of the most commonly isolated strain types recovered in community settings.  
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1.2 USA300 Virulence 
1.2.1 Spread of USA300 
Investigations of CA-MRSA outbreaks in prisons, athletic quarters, daycares, and military recruits 
have all contributed to our understanding of the development and spread of MRSA infections. 
Investigations of various outbreaks identified several critical risk factors contributing to the spread 
of infection, including sharing towels and razors, frequent skin to skin contact, unattended skin 
abrasions, and lack of attention to cleaning of environmental surfaces and athletic equipment (55). 
In addition, the high rate of antibiotic use among individuals has acted as a selective factor for 
MRSA disease. Thus, USA300 is well adapted to spread and cause infections in the community 
and healthcare settings. 
International and intercontinental spread of epidemic S. aureus strains, including MRSA type 
USA300, is not a new phenomenon, but is arguably being facilitated by increasing volumes of 
international travel and migration. Within a few years of its first description, USA300 SSTIs have 
been reported in 36 countries on five continents (56). Furthermore, autochthonous acquisition has 
been documented in Canada, 10 European countries, Colombia, Trinidad and Tobago, Israel, 
Japan, and Samoa (56). The sustained spread of CA-MRSA may, in principle, be due to the total 
number of infections and direct transmission from infected patients, and thus to infectivity or 
virulence. However, CA-MRSA may also show increased transmissibility and colonization 
characteristics due to acquisition of virulence factors encoded by unique genomic contents. 
1.2.2 Unique Genomic Contents  
Many different lineages of CA-MRSA cause outbreaks and invasive infections, but in North 
America, none are as prevalent as the epidemic strain USA300. These clones have acquired many 
genes in the form of mobile genetic elements (MGE) that may confer a selective advantage over 
other CA-MRSA strains. The USA300 chromosome can be divided into a core component, 
consisting of gene regions shared by all strains of S. aureus, and an accessory component, which 
includes gene regions that are absent in closely related strains. Virtually all unique genes in 
USA300 cluster in five novel allotypes of MGEs that encode virulence or resistance determinants, 
and the capacity of USA300 to cause severe disease is attributable to one or more of these elements.  
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The first genetic element is known as SCCmec, which encodes the mecA gene and is located on a 
MGE. There are currently eight recognized types of SCCmec, with types I, II, and III containing 
additional drug resistance determinants, and types IV, V, VI, and VII harboring resistance only to 
β-lactams through the mecA gene (57). In the absence of antibiotic pressure, the SCCmec element 
is thought to reduce the biological fitness of MRSA (58). However, strains of CA-MRSA such as 
USA300 carry the type IV allotype of SCCmec, which is smaller than the other types, and 
therefore, may impose less of a fitness cost (59). Thus, it is thought that harboring SCCmecIV, as 
opposed to other SCCmec types, imparts CA-MRSA with an advantage in its ability to cause 
infection in healthy individuals. 
Adjacent to the SCCmec element of USA300 is the pathogenicity island ACME, which is the 
largest genomic region distinguishing USA300 from other S. aureus strains, and the physical 
linkage between these two elements suggests that selection for pathogenicity and selection for 
antibiotic resistance are interconnected (59). Evidence has indicated that the initial assembly of 
the ACME locus originated in S. epidermidis or other coagulase negative staphylococci, and was 
acquired by USA300 through a single horizontal gene transfer (60). ACME encodes a complete 
arginine deiminase pathway, which converts L-arginine to carbon dioxide, ATP, and ammonia. 
Although the functional relevance of ACME to infection and disease remains unclear, the ACME 
element has been suggested to promote survival of USA300 on human skin and persistence within 
cutaneous abscesses (61). The ACME locus is composed of at least 33 putative genes and two 
operons, referred to as opp and arc (60). The opp operon encodes an oligopeptide permease or 
metal transporter, and homologous genes have been implicated in virulence of Streptococcus 
pyogenes (62). The arc operon encodes genes thought to be involved in arginine catabolism, and 
have been implicated in USA300 survival in acidic environments that mimic human skin (61). 
Host arginine feeds multiple pathways during a typical immune response; initially, macrophages 
in infected tissue primarily consume arginine via nitric oxide synthase (NOS) enzymes to generate 
nitric oxide (NO) (63, 64). However, over time, the host response shifts away from NO production 
and towards an anti-inflammatory phase, where macrophages redirect arginine consumption 
towards the production of ornithine, which can be further converted to polyamines (61, 63, 64). 
Consequently, since ACME-arc promotes long-term survival of USA300 in acidic environments 
such as the skin, it indirectly drives excessive production of host polyamines, which are uniquely 
toxic to S. aureus. To mitigate this, ACME also encodes the spermidine acetyltransferase SpeG, a 
  
10 
polyamine-resistance enzyme that is essential for combating excess host polyamines in a murine 
SSTI model (61).  
In addition to SCCmec and ACME, USA300 contains a novel staphylococcal pathogenicity island, 
SaPI5, that encodes two enterotoxins. These enterotoxins are closely related to enterotoxins SEQ 
and SEK, which are pyrogenic toxin superantigens belonging to the HA-MRSA clone COL. Since 
the SaPI5 enterotoxins of USA300 share more than 98% identity in amino acid sequences to those 
in COL, these molecular variants probably stimulate a similar subset of T cells (65). The fourth 
genetic element present in USA300 is prophage ϕSA2usa, which harbours the genes that encode 
PVL, a pore-forming toxin that induces polymorphonuclear cell death by apoptosis. PVL is 
strongly associated with invasive disease and virulence of USA300 and other CA-MRSA strains 
(66). The fifth genetic element of USA300 is prophage ϕSa3usa, encoding staphylokinase and a 
chemotaxis inhibiting protein (65). Staphylokinase is a potent plasminogen activator that could 
facilitate bacterial spreading, and the chemotaxis-inhibiting protein is an anti-inflammatory agent 
that inhibits C5a-dependent recruitment of neutrophils (67). These five genetic elements of 
USA300 most likely account for phenotypes of interest, as they carry known virulence factors and 
resistance determinants that could allow for success of USA300 in colonization and pathogenesis. 
1.2.3 Virulence Factors 
In addition to possessing antibiotic resistance, USA300 is more virulent and causes more severe 
disease than other CA-MRSA strains due to high expression of genomic virulence determinants. 
In animals, USA300 has exhibited enhanced production of dermonecrotic lesions in skin abscess 
models when compared to other MRSA clones, and USA300 was more lethal in a rat model of 
pneumonia compared with a USA400 isolate (53, 68, 69). Within abscesses, S. aureus reduces its 
expression of adhesion proteins and produces large amounts of toxins, immune evasion factors, 
and tissue degrading enzymes, all of which contribute to the remarkable pathogenicity of USA300. 
The success of CA-MRSA infection depends mostly on efficient evasion of attacks by human host 
defenses, for which S. aureus has developed many different strategies. The most crucial strategy 
that allows USA300 to invade human hosts is likely the production of toxins that kill human 
leukocytes, especially neutrophils, as they represent the main leukocyte type responsible for the 
elimination of bacterial pathogens (11). Many S. aureus toxins and virulence determinants are 
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encoded on MGEs, including the leukolytic toxins, collectively called leucocidins, and are the 
toxins responsible for destroying neutrophils after uptake. Most work has been performed on PVL, 
owing to the initially strong epidemiological correlation with CA-MRSA infections (70). PVL is 
a two-component exotoxin that forms pores in the membranes of leukocytes, causing their lysis. 
PVL has also been indicated to activate leukocytes to release pro-inflammatory cytokines, 
including IL-8, which drive inflammation (71). Although this attracts immune cells to the site of 
infection, a strong inflammatory effect may lead to tissue destruction and exacerbation of infection, 
even in the absence of leukocyte lysis. Epidemiological and clinical reports indicate a strong 
correlation between PVL production and severe SSTIs, as well as necrotizing pneumonia and 
fasciitis (72). Thus, PVL is significantly correlated with invasive CA-MRSA disease.  
Another pore-forming leukocyte toxin, α-toxin, also known as α-hemolysin, has been well 
described as a virulence factor in many S. aureus strains, including USA300. Unlike PVL, secreted 
α-toxin does not lyse neutrophils, but instead lyses other immune cells such as macrophages and 
lymphocytes. At lower concentrations, α-toxin forms a complex with a protein belonging to a 
disintegrin and metalloproteinase (ADAM) family, which allows it to form a pore in the membrane 
and cause apoptosis (73). At higher concentrations, α-toxin non-specifically absorbs into cellular 
membranes and causes the release of calcium ions and subsequent cell necrosis (74). The secretion 
of α-toxin is an important determinant of virulence in CA-MRSA models, and is consistently 
expressed at higher levels in USA300 compared to less pathogenic strains of S. aureus (75). 
Additional virulence factors that are also expressed at higher levels in USA300 include the phenol-
soluble modulins (PSMs), which have potent leukocidal and chemotactic properties, and are able 
to recruit, activate and lyse human neutrophils (76).  
Strains of S. aureus also express several secreted proteases that mediate the breakdown of host 
tissue, specifically fibrotic tissue synthesized to confine lesions containing S. aureus. As with α-
toxin and PSMs, USA300 clones are also known to excrete proteases in excess, potentially limiting 
the ability of the host to control minor SSTIs (77). These secreted proteases have been identified 
as important contributors to virulence through cleavage of specific host proteins, and S. aureus 
possesses several major secreted proteolytic enzymes. These include the serine protease SspA, the 
cysteine protease SspB, the metalloprotease Aur, and six serine-like proteases that are SspA 
homologues (SplABCDEF) (78). SspB, for example, can degrade human fibronectin, fibrinogen, 
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and kininogen, and may therefore contribute to the ability of S. aureus to disseminate (79). 
Secreted proteases can also cleave the heavy chains of all human immunoglobulin classes, and 
elastin, which aids in tissue evasion (80, 81). In addition to their interaction with the host, 
extracellular proteases are also capable of modulating the stability of self-derived virulence 
determinants. Specifically, SspA was shown to cleave surface proteins, including fibronectin-
binding protein and surface protein A (82, 83). As a result, the cleavage of these proteins by 
proteases is thought to affect the transition from an adhesive to an invasive phenotype. Several of 
the S. aureus proteases are expressed as inactive pro-enzymes that can be activated in a sequence 
known as the staphylococcal proteolytic cascade (SPC) pathway. The SPC pathway is induced in 
response to unsaturated free fatty acids, such as those encountered on the skin or in infected abscess 
tissue, and thus, acts as an environmental signal-response pathway for S. aureus to survive in these 
conditions with increased virulence (84). Similarly, it has also been suggested that extracellular 
proteases can cleave secreted toxins to regulate the abundance of virulence factors, depending on 
the specific niche encountered within the host (85). The over-production of toxins and proteases, 
in combination with the ability of S. aureus to sense changes in the environment, confers the 
selective advantage that explains the overwhelming success of the USA300 strain. 
1.2.4 Invasion of Skin Innate Immune Defenses 
Bacterial strains that cause epidemics, such as USA300, commonly combine extraordinary 
virulence with efficient colonization. The skin provides a formidable barrier to infection, yet recent 
evidence suggests an ability of USA300 to colonize the skin at higher rates than other strains (86). 
To successfully colonize, this clone must be able to evade host defense mechanisms, and the first 
line of defenses encountered are those belonging to the innate immune system. The innate immune 
system harbors a multitude of different receptor systems and cells that are constantly prepared to 
sense and eliminate invading microbial pathogens. When encountering the host, S. aureus cells 
interact with and adhere to epithelial surfaces on the skin and mucosa. Most of the defensive 
functions of the epidermis localize to the stratum corneum, the outermost layer, which limits 
pathogen colonization through its low water content, acidic pH, resident microflora, and secretions 
of polyamines and antimicrobial lipids (87, 88). Sweating and drying of the skin also means 
considerable changes in osmolarity, salt concentration and mechanical stress. Polyamines, notably 
putrescine, spermidine, and spermine, are synthesized from L-arginine and their secretion 
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facilitates countless cellular functions, including wound healing and inflammation (87). 
Interestingly, most S. aureus clones are sensitive to exogenous polyamines in culture, except for 
USA300 (65). USA300 is notably capable of growing despite the presence of polyamines due to 
speG, encoded by the ACME cassette (86).  
Another key physical feature preventing bacterial colonization of the skin is its acidic pH, which 
is the result of many factors including the secretions of lactic acid, amino acids, and fatty acids 
(89). The naturally low pH of skin and sweat (pH ~ 4.5-5.9) is well below the optimal pH of many 
bacteria, including S. aureus, and it has long been documented that patients with a higher natural 
skin pH are more susceptible to infections (90). Remarkably, USA300 is again capable of 
tolerating these acidic conditions due to the acquisition of ACME, which increases the production 
of ammonia from L-arginine catabolism, thereby countering the acidic stress (61). The constitutive 
activity of ACME drives ammonia production regardless of the presence of glucose or oxygen, a 
unique feature of ACME that sets it apart from the arginine deiminase system encoded in the 
chromosome of all S. aureus strains (61). Thus, through ACME, USA300 is better able to resist 
the acidic environment of the skin, implying a unique colonization advantage for this strain.  
Sebum, a liquid phase lipid mixture secreted from the sebaceous glands of the skin, is another 
important aspect of skin innate immune defenses, consisting of approximately 28% free fatty acids, 
32% triglycerides, 25% wax esters, and 11% squalene (91, 92). These free fatty acids contribute 
to most of the antimicrobial activity of the sebum, with the saturated fatty acid lauric acid, and the 
unsaturated fatty acid sapienic acid, being the most notable (91). The importance of sapienic acid 
as an innate defense mechanism is evident in atopic dermatitis, where the skin is deficient in this 
fatty acid, and there is a near 100% recovery of S. aureus from the skin of atopic dermatitis patients 
(93). Similarly, nasal secretions also contain antimicrobial fatty acids, primarily linoleic acid (LA), 
arachidonic acid (AA), and palmitoleic acid or their corresponding cholesterol esters, and infected 
abscess tissue also contains abundant antimicrobial fatty acids (94–96). Consequently, S. aureus 
is exposed to antimicrobial fatty acids not only during colonization, but also during infection, and 
thus it is likely that S. aureus has evolved mechanisms of intrinsic resistance. 
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1.2.5 Resistance to Antimicrobial Fatty Acids 
The human skin is rich in antimicrobial fatty acids produced by the sebaceous glands, and there is 
increasing evidence that S. aureus produces dedicated proteins that protect against the antibacterial 
activity of fatty acids. The heme coordinating surface protein, iron surface determinant A (IsdA), 
S. aureus surface protein F (SasF), and teichoic acids have all been implicated to contribute to fatty 
acid resistance (38, 97, 98). Recently, an efflux pump in S. aureus USA300 has also been 
characterized to play a role in mediating resistance to LA and AA specifically (99).  
Although different mechanisms have been put forward for the bactericidal effects of free fatty 
acids, in S. aureus, the main mechanism appears to be membrane disruption and correspondingly 
the collapse of energy metabolism, which relies on a proton gradient involving the membrane 
(100). Recent research has expanded this idea, suggesting that the accumulation of unsaturated 
free fatty acids that possess surfactant properties, such as palmitoleic acid, disrupt the phospholipid 
bilayer to such an extent that solutes such as ATP, and even larger proteins, are able to diffuse out 
(101). Since fatty acids require hydrophobic interactions for their activity, many defense 
mechanisms employed by S. aureus alter the hydrophobicity of the cell wall. One of these 
mechanisms is IsdA, which renders the cell more hydrophilic via its C-terminal domain, thereby 
leading to decreased efficiency of fatty acids at gaining access to the cell (97). Similarly, WTAs 
contribute to resistance by blocking the hydrophobic fatty acids from penetrating the cell wall and 
binding to the cytoplasmic membrane where their antimicrobial activity is exerted (38). In addition 
to these cell wall modifiers, S. aureus also secretes a fatty acid-modifying enzyme (FAME) that 
esterifies fatty acids with cholesterol or short-chained alcohols, thereby inactivating them (102).  
To combat a wide variety of host compounds, some bacteria also possess efflux pumps, for which 
fatty acids are known substrates (103). An efflux pump belonging to the resistance-nodulation-
division (RND) family of transporters has recently been identified in USA300 to confer resistance 
to LA and AA that would normally be encountered on the skin or in a tissue abscess (99). This 
novel gene pair, farR-farE (fatty acid resistance), constituting divergently transcribed genes, is the 
first known description of a dedicated and inducible mechanism of S. aureus resistance to 
antimicrobial fatty acids. The efflux of fatty acids by FarE contributes to the growth of S. aureus 
in the presence of LA, and provides one example of the diversity of substrates transported by efflux 
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pumps. There is now accumulating evidence that certain classes of efflux pumps, such as the RND 
family, not only confer resistance to drugs used in therapy, but also have a role in the colonization 
and the survival of bacteria in the host. 
1.3 The RND Superfamily  
1.3.1 Features 
Found ubiquitously in all domains of life, multidrug efflux transporters have gained recognition 
as a major contributor to many resistant bacterial infections. Efflux proteins identified to date have 
been classified into five families, and of these, proteins belonging to the RND superfamily play an 
important role in the intrinsic resistance of bacterial pathogens and confer resistance to the broadest 
range of antimicrobial agents (104). Although the importance of the RND family of transporters 
in drug resistance has made them an attractive target of new therapeutic agents, most knowledge 
of their structure and function is derived from Gram-negative bacteria and remain poorly 
understood in Gram-positive bacteria. While efflux pumps are mostly known for their transport of 
drugs from the cytoplasm, other pump substrates include sugars, lipids, proteins, synthetic 
compounds, toxic metabolites, and host defense molecules (105). Such a heterogeneous substrate 
profile allows bacterial efflux pumps to play diverse roles in drug resistance and virulence, and 
promote key physiological processes (106).  
The RND superfamily can be classified into eight recognized phylogenetic families, three of which 
are largely restricted to Gram-negative bacteria and include the heavy metal efflux (HME), the 
hydrophobe/amphiphile efflux-1 (HAE-1), and the nodulation factor exporter (NFE) families 
(107). RND pumps with features comparable to the well characterized AcrA-AcrB-TolC complex 
from Escherichia coli comprise the HAE-1 family, which are characterized for their role in 
antibiotic resistance (108). Although AcrB belongs to this subfamily, its physiologic function is 
likely to facilitate efflux of fatty acids that must be replaced due to membrane damage or 
phospholipid turnover, or to facilitate efflux of host-derived toxic compounds, including fatty acids 
and bile salts encountered in the intestine (103, 109). Similar functions of AcrB homologs in other 
species have also been reported, including in Pseudomonas aeruginosa, Neisseria gonorrhoeae, 
and Salmonella typhimurium (110–112). These observations suggest that bacterial efflux pumps, 
such as those belonging to the RND superfamily, have the capacity to transport various host-
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derived antimicrobial compounds and can therefore facilitate the adaptation and survival of 
bacteria in their ecological and physiological niches. Other phylogenetic families that make up the 
RND superfamily include (i), the SecDF family, found in both Gram-negative and -positive 
bacteria as well as archaea; (ii), the hydrophobe/amphiphile efflux-2 (HAE-2) family, restricted to 
Gram-positives; (iii), the eukaryotic sterol homeostasis (ESH) family; (iv), the 
hydrophobe/amphiphile efflux-3 (HAE-3) family; and (v), a more recently identified family that 
includes a probable pigment exporter in Gram-negative bacteria (107, 113). Extensive studies on 
the representative AcrB pump complex from E. coli in recent years have revealed both the structure 
and functional mechanisms of RND pumps in the efflux of a wide range of agents. 
1.3.2 Structure-function analysis of AcrB in E. coli 
Recent cryo-electron microscopy of the AcrA-AcrB-TolC pump structure has provided insight into 
subunit cooperation and how each of the protein components fit together into an operating machine 
(114, 115). In Gram-negative bacteria, many of these transporters form multicomponent pumps 
that span both the inner and outer membranes to efflux substrate out of the cell. The model system 
for such a pump, the AcrA-AcrB-TolC assembly, comprises the outer-membrane channel TolC, 
the secondary transporter AcrB located in the inner membrane, and the periplasmic AcrA, which 
bridges these two integral membrane proteins (114). AcrB, anchored in the inner membrane, is the 
RND protein component of this complex, while AcrA and TolC are members of the outer 
membrane factor (OMF) family and membrane fusion protein (MFP) family, respectively (116, 
117). The RND proteins of these tripartite complexes function as an energy module with the help 
of the proton motive force to efflux substrate. These three protein components form a continuous 
channel across the Gram-negative cell envelope, gathering substrates from the outer leaflet of the 
inner membrane and periplasm to the cell exterior, with the absence of any component rendering 
the entire complex non-functional. 
Although RND efflux pumps are found in all three domains of life in differing cell envelope 
architectures, these proteins share a common organization. To date, the five available RND protein 
structures (AcrB, CusA, MexB, ZneA, and MtrD) reveal that they function as homotrimers, 
wherein each protomer harbors 12 transmembrane (TM) helices, with N-terminal and C-terminal 
periplasmic domains inserted between TM1 and TM2, and between TM7 and TM8, respectively 
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(118–120). AcrB operates as a trimer, rotating through three distinct conformation states of open, 
binding, and extrusion conformations to facilitate efflux in the presence of its substrate (121). 
Recent modeling of the tripartite systems shows that, in addition to the AcrB trimer, the assembly 
comprises an AcrA hexamer and a TolC trimer (114). The AcrB trimer can be divided into a TM 
domain and an extensive periplasmic domain, comprising a distinct porter domain and a docking 
domain (122). The porter domain is located closest to the inner membrane and can be subdivided 
into four subdomains, PN1 and PN2, situated in the N-terminal portion of the protein between TM 
helices 1 and 2, and subdomains PC1 and PC2, situated in the C-terminal portion between TM 
helices 7 and 8 (122). These four subdomains meet to form proximal and distal binding pockets, 
both of which are enriched in aromatic, polar, and charged amino acid residues, forming a 
hydrophobic interior that interacts with substrates for transport (115). These two pockets might 
each contribute to the substrate poly-specificity of AcrB, as the pockets appear to have different 
substrate preferences (115, 122). Substrates may enter AcrB either from the outer leaflet of the 
cytoplasmic membrane, or from the periplasm, through three open channels, as well as a central 
cavity between the porter and TM domains (115). A vertical groove on the membrane-exposed 
surface of the protein, between TM segments 7 and 8, is suggested to provide access for membrane 
located substrates (117). The upper regions of subdomains PC1 and PC2 of AcrB are involved in 
defined interactions with specific domains of AcrA protomers (114). Also in the periplasmic 
domain, AcrB monomers are tightly interlocked and form a closed central pore, with the top of the 
protein forming a funnel-like structure, collectively called the docking domain, and is thought to 
dock TolC. The docking domain consists of subdomains DN and DC (Figure 1.2).  
Substrate efflux through the transporter is coupled with proton translocation through AcrB, and 
crystallographic evidence supports a proton pathway involving the TM domains (123). 
Specifically, asparagine and lysine located in the middle of TM helices 4 and 10 are required. 
When AcrB protomers are in their open and binding states, the asparagine side chain forms a salt 
bride with the two lysine residues, and in the extrusion conformation, the salt bridges are broken 
by internal movement (124). Therefore, protonation and conformational switching are coupled 
during transport due to structural changes of the protein that influence the environment around the 
proton pathway. In this way, the proton relay network through the pump provides energy for efflux 
via the proton motive force. 
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Increasing numbers of small proteins are being identified to interact with RND proteins but their 
functions and influences on transport are largely unknown. Small protein binding partners of AcrB, 
such as the protein known as AcrZ, have been identified to enhance transport activity of AcrB for 
certain substrates (125). AcrZ folds into a long, largely hydrophobic α-helix that fits into a wide 
groove located in the TM domain of AcrB (114). Modeling of AcrZ has shown that its N-terminus 
is positioned in the periplasm, and its C-terminus is in the cytoplasm where it interacts with the 
hydrophilic surface of AcrB near the membrane (114). However, it is still not clear as to how AcrZ 
modulates the activity of the transporter for specific substrates. Potential mechanisms could 
involve conformational changes of the substrate binding pockets, or the organization of lipids near 
the substrate portal sites (115). Given that the surface of AcrB that interacts with small proteins is 
conserved among RND family proteins, it seems likely that other RND transporters may similarly 





Figure 1.2 Secondary structure of the AcrB monomer in E. coli. The transmembrane domain 
of the AcrB monomer consists of 12 TM helices, numbered 1 to 12. The first six helices are located 
in the N-terminal portion of the protein, and the other six are located in the C-terminal portion. 
The porter domain consists of four subdomains, PN1, PN2, PC1, and PC2. The docking domain 
has two subdomains, DN and DC. N, N, C and C are -helices and -sheets of the N-terminal part or 
the C-terminal part of the periplasmic domain. N-and C-terminal portions are depicted in blue and 




1.3.3 Function in Gram-positive Bacteria and Mycobacteria 
Since Gram-positive bacteria differ in cell wall structure compared to their Gram-negative 
counterpart, the HAE-2 family of RND efflux pumps in Gram-positive bacteria are more closely 
related to the ESH family than to the Gram-negative HAE-1 proteins (107, 127). A prototypic 
member of the ESH family is the Nieman Pick Type C protein NPC1, which binds cholesterol in 
late endosomes/lysosomes and promotes its transport into the cytosol (128). One member of the 
Gram-positive HAE-2 family that is also involved in lipid transport is the mycobacterial membrane 
protein large (MmpL) proteins from Mycobacterium tuberculosis, which have been implicated in 
mediating substrate transport across the mycobacterial membrane, mainly cell wall lipids (129). 
The M. tuberculosis genome possess 15 different genes encoding RND proteins (105), 14 of which 
belong to the MmpL protein family (130). Recently, three-dimensional molecular modeling of 
MmpL transporters has revealed that these proteins have homologous structural architecture to 
other RND superfamily proteins, including AcrB (130). MmpL proteins contain a periplasmic 
headpiece and a TM region, and form a channel-like arrangement of trimeric structures. According 
to conserved domain studies, it is evident that the MmpL proteins possess AcrB, ActII, sterol 
sensing and hopanoid biosynthesis related domains, which signify similarity of the MmpL proteins 
with the well-known RND superfamily members (130). Using pairwise comparison of MmpL 
proteins with each other, two common motifs in TM helix 4 and 10 have been identified. More 
specifically, molecular modeling has shown the contribution of the conserved amino acid pair 
aspartic acid and tyrosine to the proton relay, substantiated by the fact that they are in the same 
position as the essential residues involved in the proton relay network of AcrB (124, 131, 132). 
These amino acids are highly conserved in all MmpL proteins and form an aspartic acid/tyrosine 
pair within TM helix 10. This amino acid pair, along with one additional aspartic acid residue in 
TM helix 4, serve as essential elements for the proton relay pathway in MmpL transporters (131). 
This finding was further supported in studies showing that a tyrosine to phenylalanine mutation in 
two types of MmpL pumps abolish their function, suggesting the necessity of Tyr-OH mediated 
proton transport (131).  
Since M. tuberculosis contains 15 different genes encoding RND proteins, some of these 
transporters have been found to be redundant, whereby inactivation of one pump causes increased 
activity of another. Specifically, MmpL4 and MmpL5 have redundant functions in siderophore 
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export, and a double MmpL4/5 mutant cannot be constructed, suggesting that they are essential 
for siderophore-mediated iron acquisition (133). This is comparable to RND efflux pumps 
operating in E. coli and Salmonella, as the antimicrobial susceptibility of deletion mutants and 
strains with an increased expression of certain RND efflux pumps indicates an overlap or 
redundancy between the antimicrobials, biocides, dyes and detergents that can be transported by 
the different RND pumps (134, 135). 
Also comparable to RND efflux pumps of Gram-negative bacteria, many MmpL transporters 
appear to cooperate with smaller accessory proteins called mycobacterial membrane protein small 
(MmpS), which are involved in scaffolding and are predicted to have only one N-terminal TM 
domain with an extra-cytoplasmic C-terminus (136). However, unlike most Gram-negative RND 
transporters, MmpL proteins are not believed to export antibiotics and seem to be much more 
specific for their substrate, interacting with only one lipid metabolite (136, 137). Furthermore, 
whereas RND family members from Gram-negative bacteria act purely as efflux pumps, RND 
transporters in Gram-positive bacteria may also be involved in the synthesis of certain molecules. 
For example, in M. tuberculosis, MmpL8 plays a role in the synthesis of sulfolipid-1, possibly by 
transporting a precursor of this molecule to the cell surface (136).  Indeed, it is believed that MmpL 
transporters, in conjunction with their MmpS accessory proteins, are responsible for coupling lipid 
biosynthesis and export, transporting fatty acid and lipid components that are required to produce 
the lipid rich mycobacterial cell wall, such as monomeromycolyl diacylglycerol (MMDAG), 
mycolate ester wax, trehalose monomycolate, sulfolipids, and even siderophores (105, 130, 133, 
138, 139). Most mmpL and mmpS genes are located close to genes involved in the synthesis or 
modification of polyketides, and MmpS proteins may promote interactions between various 
proteins involved in biosynthetic pathways. These small MmpS TM proteins may promote protein 
interactions via their extracytoplasmic C-terminal domains, which stabilizes the protein complex 
and enhances synthesis and export (136). This observation is apparent in some MmpL proteins 
such as MmpL11, which promotes export of mycolic acids. MmpL11 has two smaller 
extracytoplasmic domains and a large cytoplasmic C-terminal domain compared to that of AcrB. 
The large C-terminal cytoplasmic segment is thought to facilitate localization of the protein to the 
septum of dividing cells, where mycolic acid is being synthesized and exported (140). It is 
proposed that its extracytoplasmic C-terminal domain facilitates protein interaction in the 
cytoplasm, a key process for its function. Although MmpS proteins display no similarity to the 
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MFP family of Gram-negative bacteria, the close association of mmpS and mmpL genes suggests 
that MmpS proteins may be the functional homologues of MFPs. Similarly, related HAE-2 
transporters ActII-3 in Streptomyces coelicolor, and YerP/SwrP in Bacillus subtilis are also 
suggested to couple the synthesis and export of their substrates (141, 142). These observations 
suggest that microbial RND efflux pumps support physiological processes that are defining traits 
of a genus or species, and that protein-protein interactions may be essential to their function.  
1.3.4 Function in S. aureus  
Most studies on RND pump structure and function focus on those found in Gram-negative bacteria; 
however, research on RND efflux pumps in Gram-positive bacteria has become increasingly more 
prevalent. In S. aureus, three RND proteins are present: SecDF, FarE, and SAUSA300_2213, 
which is currently uncharacterized. SecDF is an accessory factor of the conserved Sec protein 
translocation machinery and belongs to the RND family of multidrug exporters. SecDF has been 
shown in both E. coli and B. subtilis to be involved in the export of proteins. In S. aureus, lack of 
SecDF affects cell separation, resistance, and virulence factor expression, suggesting its 
importance in pathogenesis (143, 144).  
Recently, through comparative genome sequencing of S. aureus USA300 variants that were 
selected for enhanced resistance to LA, a regulator of fatty acid resistance, farR, and an effector 
of fatty acid resistance, farE, were identified; this is the first description of a dedicated and 
inducible mechanism of S. aureus resistance to antimicrobial fatty acids (99). These genes bear 
similarity to the acrR and acrB model in E. coli, and protein structural modeling and homology 
searches indicate that FarR belongs to the TetR/AcrR family of regulators, while FarE belongs to 
the RND family of multidrug efflux pumps (99). Although AcrB family efflux pumps have been 
most extensively characterized as mediators of multidrug resistance, the primary function of FarE 
is to promote efflux of antimicrobial fatty acids that would be encountered during colonization or 
within a tissue abscess. This is consistent with the belief that members of the AcrB family have 
evolved to promote efflux of host-derived toxic compounds, including bile salts and fatty acids 
(99, 103). Although recent studies reveal important observations on the role of FarE in fatty acid 
efflux, functional redundancy with the third uncharacterized RND transporter in S. aureus remains 
to be investigated. 
  
23 
The SecDF and FarE transporters of S. aureus represent two of three RND-family transporters that 
are conserved among staphylococci. A third conserved RND transporter, SAUSA300_2213, that 
has not been characterized is adjacent to femX (SAUSA300_2214), a gene that is essential for 
viability of S. aureus due to its role in synthesis of the Gly5 cross-bridge structure that is a unique 
trait of staphylococcal peptidoglycan (29). This arrangement is conserved among staphylococci, 
implying that SAUSA300_2213 may have a role in transport of this structure, which is assembled 
on a lipid carrier. Importantly, synthesis of other non-ribosomal peptides/polyketides like FemX 
is a common trait in the assembly of mycobacterial glycolipid, actinorhodin of S. coelicolor, and 
lipopeptide surfactant of B. subtilis, all of which are transported by RND efflux pumps (141, 142). 
Hence, we refer to SAUSA300_2213 as FemT to denote a predicted role in transport of 
peptidoglycan precursor, however, the function of FemT and its role in cell wall synthesis remains 
to be elucidated.  
Comparing structural features, AcrB and FemT share a striking alignment of TM segments and 
extracytoplasmic domains, which were modeled using Phyre2 (145) (Figure 1.3). Phyre2 predicted 
with 100% confidence that FemT has porter and docking domains similar to AcrB. Moreover, 
FarE, FemT and AcrB all appear to share high structural conservation in their membrane domain 
segments. However, FarE has significantly smaller porter domains, and lacks a defined docking 
domain. These predictions are supported by analyses of MmpL proteins; for example, 
crystallization of the soluble D2 domain of MmpL11, which resembles the porter domain of AcrB, 
is significantly smaller (~150 residues) compared to other RND transporters (~300 residues). In 
addition, MmpL11 lacks a docking domain and contains a large C-terminal cytoplasmic segment 
(140). Although the functions and structure of RND transporters are being extensively studied in 
both Gram-negative and Gram positive bacteria, many outstanding questions remain regarding the 









Figure 1.3 Structures of AcrB, FemT, and FarE efflux pumps. AcrB is annotated from its 
known structure (122) and compared to predicted structures of FemT and FarE, which were 
modeled using Phyre2 (145). The docking domain, coloured in magenta, the porter domain, in 












1.4 Hypothesis and Research Objectives 
Although RND pumps are known to play critical roles in physiological function and antimicrobial 
resistance, the function of FemT, and the relationship between FemT and FarE in staphylococci 
have not been identified. Thus, the goal of this research was to elucidate the specific role of FemT, 
and to identify a relationship between FemT and FarE in S. aureus. We hypothesized that FemT, 
which is conserved among staphylococci, plays a role in cell wall synthesis by promoting transport 
of a peptidoglycan precursor. We further hypothesized that redundancy in substrate efflux may 
occur between FemT and FarE, as both are RND efflux pumps with implicated roles in 
physiological processes.  
To test this hypothesis, we pursued two different research objectives. The first objective was to 
evaluate the role and impact of FemT in S. aureus by examining the phenotype of a femT-deletion 
mutant. To accomplish this, the FemT-deficient mutant was evaluated for perturbations in growth 
under various growth and stress conditions. The second objective was to identify a relationship 
between FemT and FarE transporters in S. aureus, specifically by evaluating whether inactivation 
of one pump caused an increase in expression of the other pump, and assessing the extent of 
substrate redundancy among these two RND pumps. To achieve this, both farE and femT 
expression were examined in a strain deficient in either FemT or FarE, respectively. Overall, this 
detailed evaluation of the function of both RND efflux pumps operating in S. aureus will provide 
new insight into the biology of staphylococci and further our understanding of this family of 









2 Materials and Methods 
2.1 Storage and Growth of Strains 
A list of bacterial strains and plasmids that were used or constructed in this study is provided in 
Table 2.1. Cultures were maintained as frozen stocks (−80°C) in tryptic soy broth (TSB; Difco™) 
with 20% glycerol. To generate single colonies, S. aureus strains were streaked onto tryptic soy 
agar (TSA; 1.5% Difco™ Agar) plates supplemented, when required, with 10 µg/mL of 
erythromycin or chloramphenicol for propagation of strains bearing resistance markers. E. coli 
strains were grown on Luria-Bertani (LB; Sigma) agar or in LB broth containing 100 µg/mL 
ampicillin or 50 µg/mL kanamycin when required. Unless otherwise stated, inoculum cultures 
were prepared by transferring cells from a single colony into 13-mL polypropylene tubes 
containing 3 mL of broth supplemented with antibiotic, as required, followed by overnight 





Table 2.1 Strains and plasmids used in this study 
Strain or plasmid Description Source  
Strains   
S. aureus   
USA300 CA-MRSA, wild-type strain cured of resistance 
plasmids 
(84) 
RN4220 Restriction endonuclease deficient lab strain, 
capable of accepting foreign DNA 
(146) 
USA300ΔfarER USA300 with markerless deletion of farE and farR 
(SAUSA300_2489 and 2490) 
(147) 
USA300ΔfemT  USA300 with markerless deletion of femT 
(SAUSA300_2213) 
This study 
USA300ΔfarER-femT USA300 with markerless deletion of farE, farR, 




USA300 ΔfemT complemented with native femT, 




USA300 ΔfarER-femT complemented with native 
femT, cloned in pALC2073, CmR  
This study 
USA300 (pALC2073) USA300 with empty pALC2073 vector, CmR  This study 
E. coli    
DH5α λ− ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 
endA1 hsdR17(rK− mK−) supE44 thi-1 gyrA relA1 
Invitrogen 
BL21 (DE3) F- ompT gal dcm lon hsdSB (rB- mB+) λ (DE3 [lacI 





pGYlux E. coli-S. aureus shuttle vector carrying a promoterless luxABCDE operon; AmpR, CmR 
(148) 
pGYfarE::lux E. coli-S. aureus shuttle vector carrying a putative 




pKOR1 E. coli-S. aureus shuttle vector; contains xyl-tetO 
promoter, expresses antisense secY RNA; AmpR, 
CmR, TetR 
(149) 
pKORΔfemT  pKOR1 containing upstream and downstream 
flanking sequences for deletion of femT; AmpR, 
CmR, TetR 
This study 
pALC2073 E. coli-S. aureus shuttle vector with xyl/tetO 
promoter-operator region; CmR, TetR 
(150) 
pALCfemT  Native femT gene cloned in SacI site for 
expression from xyl/tetO promoter; CmR, TetR 
This study 
pET28a(+) E. coli shuttle vector; overexpression vector for 
6xHis-tagged proteins; KmR 
Novagen 
pETfemT femT porter domain cloned in NheI and BamHI 
sites for overexpression of 6xHis-tagged femT 
porter domain; KmR 
This study 
pETfarE farE porter domain cloned in NdeI and BamHI 
sites for overexpression of 6xHis-tagged farE 
porter domain; KmR  
This study 
Abbreviations: AmpR – ampicillin resistance; CmR – chloramphenicol resistance; TetR – 




2.2 DNA Methodology 
2.2.1 Plasmid Isolation from E. coli 
Plasmid DNA from E. coli strains was isolated using the Presto™ Mini Plasmid Kit (Geneaid) 
following the instructions provided by the manufacturer. Briefly, 3 mL of E. coli culture at 
stationary phase was pelleted via centrifugation and then resuspended in 200 µL Solution I             
(50 mM Tris, pH 8.0, 20 mM EDTA, 100 µg/mL RNaseA). Cells were then lysed via the addition 
of 200 µL Solution II (200 mM NaOH, 1% w/v SDS), and then incubated for 2 minutes until lysate 
became homogenous. The solution was then neutralized with the addition of 300 µL Solution III 
(guanidine hydrochloride with acetic acid), and inverted several times until a flocculent precipitate 
formed. Subsequently, samples were centrifuged for 8 minutes at 14,500 × g to pellet the insoluble 
precipitate. The supernatant was then transferred to a column and centrifuged for 1 minute. To 
wash the column, 600 µL of Wash Buffer diluted with absolute ethanol was then added to the 
column and centrifuged for an additional minute. The column was then centrifuged for 3 minutes 
to dry and remove any remaining ethanol. Plasmid DNA was then eluted from the column and into 
a microcentrifuge tube by the addition of 30 µL elution buffer (10 mM Tris-HCl, pH 8.5) to the 
column, and subsequent centrifugation at 14,500 × g for 2 minutes. 
2.2.2 Plasmid Isolation from S. aureus 
Plasmid DNA isolation from S. aureus was accomplished following the same protocol as described 
for E. coli, with the following one modification. The pellet of 3 mL S. aureus culture at stationary 
phase was resuspended in 200 µL Solution I with the addition of 50 µg/mL lysostaphin. Cells were 
then incubated at 37°C for 30 minutes to lyse the cells prior to addition of Solution II.  
2.2.3 Chromosomal DNA Isolation from S. aureus  
Chromosomal DNA from S. aureus was prepared using the GenElute™ Bacterial Genomic DNA 
Kit (Sigma) following the instructions provided by the manufacturer. In brief, 1.5 mL of S. aureus 
culture at stationary phase was pelleted via centrifugation and resuspended in 200 µL solution of 
2.1 × 106 units/mL lysozyme (Sigma) supplemented with 50 µg lysostaphin. Cells were then 
incubated at 37°C for 30 minutes to allow for lysis. After incubation, 20 µL proteinase K and      
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200 µL Lysis Solution C were added to the cells, which were then vortexed and incubated at 50°C 
for 10 minutes. Simultaneously, a GenElute Miniprep Binding Column was prepared with the 
addition of 500 µL Column Preparation Solution and subsequent centrifugation at 13,000 × g. The 
cell lysate was then prepared for binding by the addition of 200 µL absolute ethanol, followed by 
10 seconds of vortex prior to loading into the Binding Column. The column was then centrifuged 
at 5,000 × g for elution. To wash away protein contaminants, 500 µL of Wash Solution 1 was 
added to the column, followed by centrifugation at 5,000 × g. Afterwards, the column was loaded 
with Wash Solution Concentrate (containing 70% ethanol) and centrifuged for 3 minutes at   
13,000 × g to dry the column. Genomic DNA was then eluted into a new microcentrifuge tube by 
the addition of 100 µL elution solution to the column and subsequent centrifugation at 5,000 × g 
for 1 minute. 
2.2.4 Restriction Enzyme Digestions  
All restriction enzymes used in this study were purchased from New England Biolabs (NEB). 
Digestions occurred in 25 µL volumes and were incubated for 2-4 hours at 37°C. Digested DNA 
was cleaned using a GenepHlow™ Gel/PCR Kit (Geneaid) following instructions provided by the 
manufacturer. Briefly, 125 µL Gel/PCR Buffer was added to each digestion reaction and mixed by 
vortex. The sample mixture was then added to a DFH Column and centrifuged at 14,500 x g for   
1 minute. To wash the column, 600 µL of Wash Buffer diluted with absolute ethanol was added, 
and contents were centrifuged at 14,500 × g for 1 minute. The column was then centrifuged for     
3 minutes to dry and remove any remaining ethanol. DNA was then eluted from the column and 
into a microcentrifuge tube by the addition of 30 µL elution buffer (10 mM Tris-HCl, pH 8.5) to 
the column, and subsequent centrifugation at 14,500 × g for 2 minutes.  
2.2.5 DNA Ligations 
DNA ligations were accomplished using T4 DNA ligase purchased from NEB. In brief, DNA 
fragments were ligated in 20 µL volumes and were incubated at room temperature overnight. 
Briefly, a 20 µL reaction was composed of 2 µL 10 × T4 DNA ligase reaction buffer, 1 µL T4 
DNA ligase (4 × 105 units/mL), and a 5:1 molar ratio of insert to vector. 
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2.2.6 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used for separation and visualization of DNA fragments. Agarose 
gels (0.8% w/v) were prepared using a 1 × TAE buffer (40 mM Tris acetate, 1 mM EDTA) 
supplemented with 1.5 µg/mL ethidium bromide (Sigma) to allow visualization. To run gels, DNA 
samples, typically 5 µL, were mixed with 6× loading buffer and added into the well of the gel. 
Electrophoresis was performed utilizing a BioRad PowerPac 300 set at 120 V and samples were 
run for 30-40 minutes. A 1 kb ladder (NEB) was utilized to determine DNA fragment size. DNA 
fragments were visualized using a Syngene G-Box.  
2.2.7 DNA Isolation from Agarose Gels 
To isolate specific DNA fragments from restriction enzyme digestions, fragments were visualized 
with UV light and extracted from 0.8% w/v agarose gels with razor blades. DNA fragments were 
then cleaned using a GenepHlowTM Gel/PCR Kit (Geneaid) following instructions provided by the 
manufacturer. Briefly, DNA fragments were excised from the agarose gel, and gel slices were 
transferred to a 1.5 mL microcentrifuge tube. Next, 500 µL of Gel/PCR Buffer was added to the 
tube and mixed by vortex. Samples were then incubated at 55-60°C for 10-15 minutes to 
completely dissolve the agarose gel slices. Once the dissolved sample cooled to room temperature, 
the mixture was added to a DFH column and centrifuged at 14,500 × g for 1 minute. Flow-through 
was discarded and 400 µL W1 Buffer was added to the column and centrifuged for an additional 
minute. Next, 600 µL Wash Buffer diluted with absolute ethanol was added to the column and 
contents were centrifuged at 14,500 × g for 1 minute. The column was then centrifuged for an 
additional 3 minutes to dry and remove any remaining ethanol. DNA was then eluted from the 
column and into a microcentrifuge tube by the addition of 30 µL elution buffer (10 mM Tris-HCl, 
pH 8.5), and subsequent centrifugation at 14,500 × g for 2 minutes. 
2.2.8 Polymerase Chain Reaction (PCR) 
PCR reactions occurred in 50 µL volumes following protocols outlined by GenScript. A 50 µL 
reaction was composed of 5 µL 10 × Taq buffer containing Mg2+, 1 µL 10 mM dNTP, 1 µL forward 
primer (100 µM), 1 µL reverse primer (100 µM), 1 µL template DNA (1-100 ng/µL), 40.5 µL 
sterile Milli-Q water, and 0.5 µL Taq polymerase (5 units/µL). Oligonucleotides used in this study 
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are listed in Table 2.2. PCRs were carried out utilizing a PTC-100 Programmable Thermal 
Controller (MJ Research Inc.) optimized for specific primer annealing temperatures and DNA 
fragment lengths.  
2.2.9 Nucleotide Sequencing 
Nucleotide sequencing was performed at the London Regional Genomics facility of the Robarts 
Research Institute (London, ON) with samples prepared according to their specifications. In brief, 
10 µL DNA (50-150 ng/µL) and 5 µL oligonucleotide primer (20 µM) were combined and sent for 
analysis.  
2.2.10 Computer Analyses 
Analyses of sequenced DNA and designing of primers were completed with MacVector 
(MacVector, Inc, Cambridge, United Kingdom). Protein and DNA BLAST searches were 
accomplished utilizing the National Center for Biotechnology Information (NCBI) website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
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Table 2.2 Oligonucleotides used in this study 











GYfarE_Ff cccggatccTTGTACGGTGTACGAGTGCG  
GYfarE_Rg cccgtcgacCGGTGCATTTGTAGCAAGTG  
femT::lux_Bamf gattatgtattgaatcagccatggatccAATTAATTGAGCAAGTTAAACC 
femT::lux_Salg ctaatttcaatttagcagtcgacTATACACCGCCCAAGA 
femT_Port Fh aacacagctagcTTTGGAGGACCGAGACTAGGCAC 




aLower case denotes 5′ additions. Restriction sequences are underlined. 
bSacII 
cattB1 site for cloning in pKOR1: GGGGACAAGTTTGTACAAAAAAGCAGGCT 









2.3 Transformation Methodologies 
2.3.1 Preparation of Transformation Competent E. coli  
Calcium chloride competent E. coli DH5α or BL21 (DE3) cells were prepared for transformation 
following an established lab protocol (151). Briefly, the optical density (OD) of overnight 
stationary phase DH5α cells was measured at 600 nm wavelength (OD600) using a Beckman 
Coulter spectrophotometer, and the volume equivalent of 0.01 OD600 was sub-cultured into          
400 mL LB. When this culture reached mid-exponential phase (OD600 ~0.5), cells were placed on 
ice to cool for 20 minutes. The culture was then pelleted at 4,000 × g at 4°C for 10 minutes, and 
washed through resuspension in 100 mL ice cold 0.1 M CaCl2 containing 15% glycerol (v/v). This 
mixture was then left on ice for 30 minutes and centrifuged again to pellet cells. After 
centrifugation, the supernatant was discarded and the pellet was resuspended in 4 mL 0.1 M CaCl2, 
15% glycerol (v/v) to aliquot into 100 µL volumes. Competent cells were then flash frozen and 
placed in a -80°C freezer for storage until future use.  
2.3.2 Transformation of Competent E. coli  
Calcium chloride competent E. coli DH5α or BL21(DE3) cells were transformed with plasmid 
prepared via techniques described above. Once prepared, 5 µL plasmid or 10 µL ligation mixture 
was added to an aliquot of thawed competent E. coli cells and incubated on ice for 30 minutes. 
Subsequently, cells were heat shocked at 42°C for 2 minutes to allow DNA to enter the cells, 
followed by a 2-minute incubation on ice. Cells then received 900 µL LB containing relevant 
antibiotics at a 1/10 dilution and left to resuscitate at 37°C. Cells were incubated for 1 hour to 
allow recovery before plating on LB agar containing selective antibiotics. Plates were grown 
overnight at 37°C and examined for single colonies the following day.  
2.3.3 Preparation of Transformation Competent S. aureus  
Electro-competent S. aureus RN4220, USA300, and USA300 derivatives were prepared for 
transformation utilizing established lab protocols (146). Overnight stationary phase S. aureus cells 
were used to inoculate 400 mL TSB to an OD600 of 0.01. When this culture reached mid-
exponential phase (OD600 ~ 0.5), cells were placed on ice to cool for 10 minutes. The culture was 
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then pelleted at 4,000 × g at 4°C for 10 minutes, and washed through resuspension in 40 mL ice 
cold 0.5 M sucrose. This mixture was then left on ice for 20 minutes and centrifuged again to pellet 
cells. After centrifugation, the cell pellet was resuspended in 5 mL 0.5 M sucrose, and centrifuged 
a second time. The new pellet was then resuspended in 4 mL 0.5 M sucrose and aliquoted into    
100 µL volumes. Competent cells were then flash frozen and placed in a -80°C freezer for storage 
until future use.  
2.3.4 Transformation of Competent S. aureus  
Electro-competent S. aureus cells were transformed with plasmid extracts prepared from other 
cells. All recombinant plasmids were first constructed as shuttle vectors in E. coli DH5α. The 
integrity of plasmids isolated from E. coli was confirmed by restriction enzyme digestion and 
nucleotide sequencing of the cloned DNA fragments, as described previously, prior to introduction 
into S. aureus RN4220. Importantly, RN4220, a restriction endonuclease deficient strain, could be 
transformed with plasmid from E. coli and was used as an intermediate host prior to introduction 
into USA300 and its isogenic variants. To transform competent S. aureus, 3 µL of plasmid was 
added to an aliquot of thawed competent cells and incubated on ice for 30 minutes. The cell mixture 
was then transferred to a col 2 mm electroporation cuvette (VWR) and electroporated using a Bio-
Rad Gene Pulser II, set to 2.5 KV, 200 Ω, and 25 µF. Electroporated cells then received 900 µL 
TSB containing relevant antibiotics at a 1/10 dilution and left to resuscitate at 37°C. Cells were 
incubated for 1 hour to allow recovery before plating on TSA containing selective antibiotics. 
Strains transformed with larger plasmids (>10 kb) were plated with top agar (0.8% agar) to provide 
a slower introduction to antibiotics. Plates were grown overnight and examined for single colonies 
the following day. 
2.4 Mutagenesis and DNA Cloning Methods 
2.4.1 Generation of an In-Frame Mutation  
Deletion of the femT gene was generated utilizing the temperature sensitive plasmid pKOR1 (149). 
This plasmid possesses several important features to allow in-frame deletion of genes, including 
the cat gene to encode chloramphenicol resistance for positive selection, the attP sequences to 
allow recombination with genetic material possessing attB sequences, and the repF gene to permit 
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replication at 30°C, but not at 42°C. It also possesses a tetR and secY570 cassette to allow for 
negative selection utilizing anhydrotetracycline (aTc), which drives production of antisense secY 
that inhibits bacterial growth and survival. For construction of a femT deletion, two sequences of 
approximately 1 kb flanking the femT gene were amplified with the primers FemTUP_attB1 and 
FemTUP_SacII for the upstream segment, and FemTDW_SacII and FemTDW_attB2 for the 
downstream segment (Figure 2.1). Once amplified, the downstream and upstream segments were 
digested with SacII and ligated to produce a fusion of the upstream and downstream segments 
flanking femT. This 2-kb construct was then cloned into pKOR1 through site-specific 
recombination between the attP and attB sites utilizing Gateway® BP Clonase II (Life 
Technologies) following instructions provided by the manufacturer. In brief, DNA fragments were 
recombined in a 10 µL reaction volume containing 15-150 ng attB product, 1 µL BP Clonase II, 
150 ng pKOR1 plasmid, and TE buffer. The reaction was incubated for 4 hours at room 
temperature, generating pKORΔfemT. The plasmid was subsequently transformed into E. coli 
DH5α and after confirmation by SacII digestion and nucleotide sequencing of the cloned fragment, 
was transformed into S. aureus strain RN4220 as described previously. After selection for 
chloramphenicol resistant colonies at 30°C, plasmid was extracted and transformed into wild-type 
USA300 and USA300ΔfarER through electroporation. To promote integration of pKORΔfemT 
into the target gene via homologous recombination, 3 mL cultures were incubated at 32°C for          
2 hours, after which the temperature was increased to 42°C. After overnight incubation, cells were 
plated on TSA supplemented with chloramphenicol and incubated at 42°C to select for integration 
of the plasmid with the target gene. Single colonies were then selected and grown at 30°C with 
shaking to allow the plasmid to excise from the chromosome. These cultures were then plated on 
TSA with aTc (20 µg/mL) to select for colonies cured of the plasmid, as the lethal antisense secY 
on pKOR1 is induced by aTc. Colonies were subsequently screened for sensitivity to 
chloramphenicol, confirming the removing of the plasmid. Deletion of femT in both USA300 and 
USA300ΔfarER was confirmed via PCR and nucleotide sequencing. An overview of femT mutant 






Figure 2.1 Genetic organization of the femT region for pKOR1 markerless mutagenesis. Map 
of femT (SAUSA300_2213) with primers annotated for pKOR1 mutagenesis. The region between 
the femT upstream and downstream segments are ligated together following SacII digestion. attB 




















Figure 2.2 Construction of femT mutant using pKOR1 markerless mutagenesis.  (A) Map of 
the pKOR1 plasmid. pKOR1 encodes repF (replication gene), secY570 (N-terminal 570 
nucleotides of secY), cat (chloramphenicol acetyltransferase), attP (phage lambda attachment site), 
ori(-) (plasmid replication origin), and bla (β-lactamase). attP sequences allow recombination with 
attB sequences. (B) Map of pKOR1 with ΔfemT fusion inserted; not to scale. (C) Hypothetical 
integration of pKORΔfemT into the genome by homologous recombination. Blue and grey shapes 
represent genes in the pKOR1 plasmid, while the green arrows indicate genes present in the 
USA300 genome. (D) The pKOR1 plasmid is excised with genomic femT, resulting in the deletion 
of femT and the insertion of the upstream-downstream fusion in the genome. Bacteria were then 
selected for plasmid loss. 
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2.4.2 Construction of pGYlux Reporter Strains  
To construct pGYfarE::lux and pGYfemT::lux reporter strains, where the promoter of farE or femT 
drives expression of the luciferase operon, a fragment containing the promoter site of the gene was 
first amplified. For pGYfarE::lux, a 396-bp fragment containing the promoter site for farE was 
amplified via PCR with the primers GYfarE_F and GYfarE_R (Table 2.2). For pGYfemT::lux, the 
primers femT::lux_Bam and femT::lux_Sal were used to amplify a 276-bp fragment containing 
the predicted promoter site of femT. After PCR amplification, clean up, and digestion with 
endonucleases BamHI and SalI, these segments were ligated into pGYlux, which had previously 
been digested with BamHI and SalI. Both recombinant plasmids were first constructed as shuttle 
vectors in E. coli DH5α. The integrity of plasmids isolated from E. coli was confirmed by 
restriction enzyme digestion and nucleotide sequencing of the cloned DNA fragments prior to 
electroporation into S. aureus RN4220 as an intermediate host. From RN4220, the individual 
plasmids were then introduced, via electroporation, into USA300 or isogenic derivatives as 
required. 
2.4.3 Construction of pET28 Recombinant Plasmids  
To construct pETfemT and pETfarE recombinant plasmids, primers were designed according to 
the porter domain sequence of femT, and the C-terminal cytoplasmic segment of farE. For the 
porter domain of femT, a 900-bp fragment was amplified via PCR with the primers femT_Port F 
and femT_Port R (Table 2.2). For amplification of the C-terminal cytoplasmic domain of farE, a 
471-bp fragment was amplified using the primers MMP_pET28_FP and MMP_pET28_RP. After 
PCR amplification, clean up, and digestion with endonucleases NheI and BamHI for femT, and 
NdeI and BamHI for farE, these segments were ligated into pET28a(+), which was digested with 
the same restriction enzymes, generating the recombinant plasmids pETfemT and pETfarE. The 
E. coli strain BL21 (DE3) was used for transformation of both recombinant plasmids. The 
transformed bacteria were selected by screening the colonies on kanamycin (50 µg/mL) containing 
media and subsequent plasmid purification. Positive colonies were confirmed by restriction 
enzyme digestion and nucleotide sequencing.  
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2.4.4 Complementation of Mutants  
To restore femT in deficient strains, the vector pALC2073 was used. Briefly, PCR conducted with 
primers pALCfemT_FP and pALCfemT_RP (Table 2.2) was performed to amplify femT. This 
product was then digested with SacI and ligated into the pALC2073 shuttle vector, creating 
pALCfemT. After transformation into E. coli DH5α, colonies were screened through restriction 
enzyme digest and sequencing to determine the orientation of the femT insert with respect to the 
xyl/tetO promoter. Fragments confirmed in the correct orientation were then electroporated into 
RN4220 before being introduced into USA300 isogenic derivatives. To induce expression of femT 
from the xyl/tetO promoter, 20 ng/mL aTc was added to cultures containing pALCfemT.  
2.5 Protein Methodologies 
2.5.1 SDS-PAGE 
Proteins in culture were assessed using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) (152). Protein samples were prepared and resuspended in 1 × Laemmli loading 
buffer (4 × buffer: 240 mM Tris-Cl pH 6.8, 8% w/v SDS, 40% v/v glycerol, 20% β-
mercaptoethanol, 0.01% bromophenol blue and milli-Q water). The entire sample and a pre-stained 
protein ladder (Frogga Bio) were then loaded into a 12% bis-acrylamide gel and run at 100 V for 
approximately 90 minutes. The separated protein bands were then stained for 18 hours with 
Coomassie blue stain for visualization, or transferred onto a membrane for Western blotting. 
Stained gels were then destained with buffer composed of 40% methanol, 10% acetic acid, and 
50% dH2O by volume, and visualized. 
2.5.2 Expression and Purification of Recombinant FemT and FarE 
For purification of FemT and FarE, a single colony of E. coli BL21 (DE3) with pETfemT or 
pETfarE was incubated in 30 mL LB, containing 50 µg/mL kanamycin, overnight at 37°C with 
shaking. The next day, the entire 30 mL culture was added to 1 L LB broth and grown at 37°C 
with shaking to an OD600 of ~0.7. Isopropyl-β-D-thiogalactopyranoside (IPTG) was then added to 
a final concentration of 0.5 mM for expression of FemT and FarE. The cells were then grown for 
an additional 18 hours at room temperature with shaking, after which cells were collected via 
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centrifugation at 3,000 × g for 12 minutes at 4°C. The cell pellets were then resuspended in 30 mL 
binding buffer (10 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole, filter sterilized). The 
cells were then lysed using a cell disrupter (Constants Systems Ltd.) at 30 psi, and cultures were 
centrifuged at 4,000 × g for 15 minutes at 4°C. From this point, any remaining cellular debris in 
the BL21 (DE3) pETfemT culture was removed by ultracentrifugation at 50,000 × g for 45 minutes 
at 4°C in a Beckman Coulter Optima® L-900K ultracentrifuge. For BL21 (DE3) cultures 
containing pETfarE, the pelleted debris after cell disruption was resuspended in 30 mL buffer B 
(100 mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, adjusted to pH 8.0) for denaturing conditions to 
solubilize inclusion bodies. The pellet was incubated in buffer B for 1 to 2 hours with agitation 
prior to ultracentrifugation at 50,000 × g for 45 minutes at 4°C in a Beckman Coulter Optima® L-
900K ultracentrifuge. After ultracentrifugation, the soluble lysate of both cultures was passed 
through a 0.45 µM nylon filter (VWR) before being passed through a nickel-loaded 1-mL HisTrap 
column (GE Healthcare) equilibrated with binding buffer or urea buffer for FemT and FarE 
samples, respectively. The 6×His-tagged FemT protein was eluted from the column with a gradient 
of 0.1 M to 0.5 M imidazole. Conversely, FarE protein was eluted from the column with two passes 
of buffer B adjusted to pH 5.9, and two passes of buffer B adjusted to pH 4.5. Eluted fractions 
were analyzed via SDS-PAGE on a 12% bis-acrylamide gel run at 100 V for approximately 90 
minutes to determine which fractions contained the highest amount of purified protein. FemT 
fractions eluted with 0.2, 0.3, and 0.4 M imidazole were then combined, and FarE fractions eluted 
with the second pass of buffer B pH 5.9 and both passes of buffer B pH 4.5 were combined. 
Combined fractions were then dialyzed overnight at 4°C against 10 mM Tris pH 8.0. Protein purity 
was then confirmed using SDS-PAGE, described above, and protein concentrations were 
determined through Bradford assay using the Bio-Rad Protein Assay Dye (Bradford) Reagent 
Concentrate (5X). Samples were read at absorbance OD595 and a standard curve was made for each 
concentration determination with 1 mg/mL bovine serum albumin (BSA). 
2.5.3 Western Blot 
Rabbit polyclonal antisera recognizing FarE and FemT were generated by ProSci (Poway, CA) 
with protein prepared as described above. For blots with FemT antisera, single colonies of S. 
aureus USA300 or its isogenic variants were inoculated in 3 mL TSB, supplemented with 
antibiotics, if necessary, and incubated at 37°C for 8 hours with shaking. Cultures were then sub-
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cultured into 25 mL TSB at a volume equivalent to 0.01 OD600 and incubated at 37°C for 18 hours 
with shaking. Conversely, for blots with FarE antisera, single colonies of S. aureus USA300 or its 
isogenic variants were inoculated in 3 mL TSB, supplemented with antibiotics, if necessary, and 
incubated at 37°C for 18 hours with shaking. Cultures were then sub-cultured at a volume 
equivalent to 0.01 OD600 into 25 mL TSB supplemented with 20 µM LA (Sigma) and 0.1% DMSO 
(v/v) (Sigma), and incubated at 37°C to mid-exponential phase, or an OD600 of ~0.5. After 
incubation, all cultures were harvested by centrifugation at 3,000 × g for 15 minutes, and cells 
were washed with 1 × PBS to remove residual media. After additional centrifugation, the pellet 
was resuspended in 3 mL lysis buffer (150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 
8.0, 1% (v/v) Triton X-100, 0.5% (v/v) SDS, 5 µg lysostaphin) and incubated at room temperature 
for 2 hours with agitation. Samples were then centrifuged at 4,200 × g for 20 minutes and 
supernatant was collected in a new tube. Protein concentrations were determined through Bradford 
assay using the Bio-Rad Protein Assay Dye (Bradford) Reagent Concentrate (5X). Samples were 
read at absorbance OD595 and a standard curve was made for each concentration determination 
with 1 mg/mL BSA. Samples were then aliquoted in volumes equal to 25 µg protein along with   
10 µL 1 × Laemmli buffer and mixed by vortexing. This mixture was then incubated at 37°C for 
30 minutes and loaded onto a 10% bis-acrylamide gel and separated by SDS-PAGE.  
  Resulting protein bands on the gel were then transferred onto a FluoroTrans PVDF 
membrane (PALL Life sciences) in a system submerged in transfer buffer consisting of 200 mL 
methanol, 14.4 g glycine, and 3.03 g of Tris filled to 1 L with dH2O (153). The membrane was 
then incubated overnight with blocking buffer (1 g skim milk powder (EMD) with 20 mL with      
1 × PBS). The next day, the membrane was incubated in 25 mL 1 × PBS supplemented with 0.1% 
tween20 (Sigma) (PBS-T) and 0.5 g skim milk powder with rabbit polyclonal antiserum diluted 
1:1000 and incubated for 2 hours at room temperature. After incubation, the membrane was 
washed three times with PBS-T for 10-minute time periods. The blot was then incubated for 
another 2 hours at room temperature with secondary antibody, anti-rabbit IgG conjugated to IRDye 
800 (Li-Cor Biosciences, Lincoln, NE), at a 1:20000 dilution. After incubation, the blot was 
washed three time with PBS-T for 10-minute periods, and washed a final time with 1 × PBS for 
10 minutes prior to scanning on a Li-Cor Odyssey Infrared Imager (Li-Cor Biosciences) and 
visualized using Odyssey V3.0 software. 
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2.6 Experimental Methodologies 
2.6.1 Growth Analysis 
To evaluate the effect of different conditions on the growth of S. aureus USA300 or its isogenic 
variants, overnight cultures were inoculated into 25 mL volumes of media at the volume equivalent 
of 0.01 OD600 and supplemented with indicated concentrations of fatty acids or other reagents. 
Unless otherwise indicated, all growth assays were conducted in 125 mL Pyrex Erlenmeyer flasks 
and cultures were incubated in a 37°C incubator with orbital shaking at 180 rpm. Measurements 
of OD600 were taken at hourly intervals. Liquid growth media used for analysis included Mueller-
Hinton broth (MHB; Sigma), brain-heart infusion (BHI; VWR) broth, and Roswell Park Memorial 
Institute (RPMI; Gibco) broth. All solutions and media were made using water purified with Milli-
Q water purification system (Millipore). 
2.6.2 Bactericidal Assays 
Overnight pre-cultures were inoculated at a volume equivalent to 0.01 OD600 into flasks containing 
25 mL TSB supplemented with 20 µM LA (Sigma) and 0.1% DMSO (v/v) to ensure fatty acid 
dissolution. A 5-mM stock solution of LA was produced by diluting pure fatty acids in 5 mL TSB 
with vigorous vortexing. These cultures were then grown to mid-exponential phase (2-3 hours; 
OD600 ~0.5) and inoculated into 25 mL fresh TSB containing a bactericidal (100 µM) concentration 
of LA and 0.1% (v/v) DMSO and grown at 37°C with shaking. To determine bactericidal activity, 
aliquots were withdrawn at hourly intervals, and diluted and plated on TSA at 100 to 103 dilutions 
with quadruplicate technical replicates. After incubation overnight, colonies were counted and 
viable CFU/mL counts were determined.  
2.6.3 Luciferase Assays 
Luciferase assays were conducted using growth analysis conditions described above. Cultures 
harboring pGYlux, pGYfemT::lux, or pGYfarE::lux plasmids were prepared in triplicate flasks 
and grown in specified conditions. At indicated time points, aliquots were removed from each 
culture for OD600 measurements, and concurrently, 4 × 200 µL technical replicates were withdrawn 
from each flask for quantification of luciferase activity. Specifically, each 200 µL aliquot was 
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added to individual wells of a flat-bottom, opaque white 96-well microtiter plate (Greiner Bio-
One). The wells were then supplemented with 20 µL 0.1% (v/v) decanal in 40% ethanol, followed 
by immediate measurement of luminescence utilizing a Biotek Synergy H4 Hybrid Reader, with 
an integration time of 1 second and a gain of 200. Luminescence background was removed from 
the relative light unit (RLU) measurements by averaging the technical replicates and subtracting 
the observed RLU from the promoterless pGYlux reporter. These data were then standardized by 
dividing individual RLU readings with the OD600 reading of the culture, producing RLU/OD600 
measurements. 
2.6.4 Lysis Assays 
Cultures of S. aureus USA300 or its isogenic variants were grown in 3 mL TSB overnight at 37°C. 
Cells were then inoculated at a volume equivalent to 0.01 OD600 into flasks containing fresh            
25 mL TSB and grown with shaking at 37°C to an OD600 of ~1.0. Cells were harvested by 
centrifugation (4,000 × g; 10 min) and washed twice with phosphate-buffered saline (PBS). The 
pellet was then resuspended in either 1 × PBS to an OD600 of 1.0, used as a control, or in 1 × PBS 
to an OD600 of 1.0 in the presence of a cell wall stressor, including Triton X-100, lysostaphin, or 
lysozyme. Cultures were then incubated at 37°C with shaking. Cell lysis was measured as a 
decrease in OD600 over time and represented as percent of initial OD600, calculated by subtracting 
individual OD600 readings at timely intervals with the initial OD600 at time zero. 
2.6.5 Antibiotic Susceptibility Assays 
To evaluate the minimum inhibitory concentration (MIC) of several antibiotics, cultures of 
USA300 or its isogenic variants were grown in 3 mL MHB overnight at 37°C with shaking. Cells 
were then inoculated at a volume equivalent to 0.01 OD600 into flasks containing fresh 25 mL 
MHB and grown with shaking at 37°C to an OD600 of ~0.5, and turbidity was adjusted so that it 
was equal to that of a McFarland 0.5 standard. A total of 100 µL of the 0.5 McFarland suspension 
was plated on a Mueller-Hinton agar plate. When the surface of each plate had dried, one 
Epsilometer test (E-test) strip was placed in the centre of each plate. Plates were then incubated at 
37°C for 24 hours. MICs in µg/mL were read directly from the test strip according to the 
instructions provided by the manufacturer, where the elliptical zone of inhibition intersected with 
the MIC scale on the test strip.  
  
45 
2.6.6 Statistical Analysis 
All data generated by the assays described above were plotted using Graphpad PRISM software, 
version 6.0f. Significance at specific points was determined using unpaired one-tailed Student’s t-





























3.1 Evaluation of the Role of FemT in Cell Wall Synthesis 
3.1.1 Deletion of the femT locus 
The first objective of this study was to determine the role of the RND efflux pump encoded by 
femT (SAUSA300_2213). The femT gene is 3,168 bp and encodes a protein containing 1,055 
amino acids, with a predicted molecular mass of 114.7 kDa. To assess the importance of FemT 
during growth, a femT deletion was constructed in a wildtype USA300 background, generating 
USA300ΔfemT, and in a USA300 background with farER deleted, producing USA300ΔfarER-
femT, as described in the Materials and Methods section. A diagram of the femT locus with 
indicated primers for PCR screening is illustrated in Figure 3.1A. PCR amplification with the 
femT_Del_F2 and femT_Del_R2 primers across the femT locus of wildtype S. aureus USA300 
and both mutants, USA300ΔfemT and USA300ΔfarER-femT, confirmed the deletion of femT in 
both strains (Figure 3.1B). With these PCR primers, the expected size of wild-type USA300 is 
4,070 kb and the size of the product amplified for the femT deletions is expected to be 900 kb. In 
addition, the femT mutation was confirmed through nucleotide sequencing using primers further 
upstream and downstream of the femT locus, femT-DEL_For and femT-DEL_Rev. PCR was also 
used to confirm the deletion of farER once USA300∆farER-femT was created. Western blot 
analysis of USA300, femT mutants, and complemented femT mutants was also performed with 
specific antibodies generated against FemT (Figure 3.1C). Membrane fractions of each sample 
were used for analysis, and 25 ng protein was loaded into each well for detection. Detected FemT 
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Figure 3.1 Confirmation of femT deletion. (A) Map of the femT locus with primers, indicated 
by blue arrows, used for PCR amplification. (B) Genomic DNA of wildtype USA300 and the 
deletion mutants USA300ΔfarER-femT and USA300ΔfemT was used as a template for PCR with 
primers flanking the femT region. (C) SDS-PAGE stained with Coomassie blue for visualization 
of FemT porter domain used for antibody production. The predicted molecular mass of the FemT 
porter domain is 42 kDa. (D) Western blot with FemT antisera confirming the deletion and 
complementation of femT. Membrane fractions of each sample were used for detection; 25 µg of 

















3.1.2 Deletion of femT improves growth of USA300 in Mueller-Hinton broth 
To assess the importance of FemT on the growth of USA300, cultures of USA300 and RND pump 
mutants USA300∆farER, USA300∆femT and USA300∆farER-femT were grown in different types 
of media. Specifically, four different types of liquid growth media were chosen for analysis, 
namely TSB, BHI broth, MHB, and RPMI media. TSB and BHI were chosen as nutritious, general-
purpose growth media that are widely used for cultivating S. aureus. Conversely, MHB and RPMI 
media were chosen for comparison as they are more depleted in nutrients. More specifically, both 
MHB and RPMI lack glucose and contain only free amino acids as a source of protein, compared 
to TSB and BHI, which both contain glucose and more complex forms of protein such as peptone. 
Since glucose is not present in MHB and RPMI, S. aureus must grow on non-preferred carbon 
sources to facilitate gluconeogenesis. In addition, much antibiotic work employs Mueller-Hinton 
medium, and the fatty acid composition of S. aureus membrane glycerolipids has shown to be 
altered when grown in MHB compared to TSB (154). Upon analysis, no difference in growth was 
observed between USA300 and the three RND pump mutants in TSB, BHI, and RPMI media 
(Figure 3.2). However, when these strains were cultured in MHB, USA300∆femT appears to reach 
the logarithmic phase of growth faster than wildtype USA300 and the two other mutants. 
Therefore, the deletion of femT does not affect the growth of USA300 in TSB, BHI, and RPMI, 













Figure 3.2 Growth analysis of USA300 and RND pump mutants in TSB, BHI, MHB, and 
RPMI. Growth of USA300, USA300∆farER, USA300∆femT and USA300∆farER-femT cultured 
in (A) TSB, (B) BHI, (C) MHB, and (D) RPMI. Each data point represents the mean value of 
triplicate cultures; error bars represent the standard error of the mean. 





























































3.1.3 USA300∆femT is more susceptible to lysostaphin 
To test our hypothesis of FemT involvement in cell wall synthesis, we investigated the potential 
effect of two cell wall stressors on lysis of USA300 and USA300∆femT. Cells were incubated with 
the metalloendopeptidase lysostaphin, which cleaves the cross-linking Gly5 bridges in the cell 
wall, or incubated with the glycoside hydrolase lysozyme, which catalyzes the hydrolysis of 1,4-
β-linkages between MurNAc and GlcNAc residues in peptidoglycan. The lytic activity of 
lysostaphin was compared between USA300 and USA300∆femT to determine if the Gly–Gly bond 
in the Gly5 crossbridge was altered in the mutant. Gründling et al. have demonstrated that 
truncations in staphylococcal cross bridges, of either one glycine or three glycine units, causes the 
observed increase in lysostaphin resistance of staphylococci (155). Additionally, Morikawa and 
co-workers using S. aureus N315 showed that cell wall thickness also plays important roles in 
lysostaphin sensitivity, whereby S. aureus cells with thinner envelopes demonstrated increased 
sensitivity to lysostaphin (156). Although S. aureus peptidoglycan is completely resistant to the 
hydrolytic activity of lysozyme, this is a function of a number of factors, including the wall teichoic 
acid composition, the degree of peptidoglycan cross-linking, and the degree of peptidoglycan 
acetylation (157). Therefore, sensitivity to lysozyme was also investigated as a potential marker 
of the influence of femT on cell wall integrity. To evaluate the sensitivity of USA300 and 
USA300∆femT in both conditions, the decline in OD600 of triplicate cultures was measured 
following the addition of 1 mg/mL lysozyme, or 50 ng/mL lysostaphin. USA300 and 
USA300∆femT were first grown in MHB to an OD600 of ~1.0, and cells were then resuspended in 
PBS as a control, or PBS containing one of the two stressors. 
Although previous research has indicated that 0.8 mg/ml lysozyme is sufficient to differentiate 
lysozyme sensitive mutants from wild type S. aureus (158), USA300 and USA300∆femT exhibited 
little to no lysis after 2 hours of incubation in 1 mg/ml lysozyme, as illustrated by a similar decline 
in their ODs over time (Figure 3.3A). However, when cell lysis was determined in the presence of 
lysostaphin, USA300∆femT cells lysed significantly more at indicated time points compared to 
USA300, as illustrated by a more rapid decline in OD600, graphed as percent of initial OD (Figure 
3.3B). This indicates that USA300∆femT is more susceptible to lysostaphin-induced cell lysis 




Figure 3.3 Deletion of femT increases sensitivity of USA300 to lysostaphin. Lysis assays of 
USA300 and USA300∆femT were carried out with cells resuspended in PBS alone (open symbols), 
or in PBS containing (A) 1 mg/mL lysozyme, and (B) 50 ng/mL lysostaphin. OD600 measurements 
were taken at timely intervals and data points were calculated as a percentage of their initial OD600. 
Each data point represents the mean value of triplicate cultures; error bars represent the standard 
error of the mean. Significant differences in % initial OD600 of cultures exposed to lysostaphin 





















































3.1.4 Deletion of femT slightly increases sensitivity of USA300 to select 
antibiotics 
To test our hypothesis that FemT contributes to cell wall synthesis and integrity, we evaluated the 
sensitivity of USA300 and the RND pump mutants USA300∆farER, USA300∆femT and 
USA300∆farER-femT to various antibiotics. Sensitivity to daptomycin was tested, as this 
membrane-active antibiotic has been shown to induce femT transcription 2.0-fold (159). 
Vancomycin, a glycopeptide antibiotic, and oxacillin, a β-lactam, were also evaluated, as they both 
inhibit cell wall synthesis. Specifically, vancomycin binds to the stem peptide of the membrane-
anchored lipid II precursor at its dipeptide moiety, Lys-D-Ala-D-Ala residue, and thus prevents 
the precursor from being incorporated into the nascent peptidoglycan chain (160–162). Oxacillin, 
as a β-lactam antibiotic, inhibits cell wall synthesis through binding and inactivating PBPs. 
To assess the sensitivity of USA300 and RND mutants to these antibiotics, MIC evaluations were 
performed using E-test strips, as described in the Materials and Methods section. When plated on 
Mueller-Hinton agar plates with a daptomycin E-test, all four cultures were shown to be equally 
sensitive to daptomycin, with an MIC of 1 µg/mL (Figure 3.4A). USA300 was slightly less 
susceptible to vancomycin, with an MIC of 2 µg/mL, compared to the three RND pump mutants, 
which all had the same MIC of 1 µg/mL (Figure 3.4B). Interestingly, USA300 and USA300∆farER 
were equally sensitive to oxacillin, with an MIC of 0.12 µg/mL (Figure 3.4C).  However, the femT 
mutants, USA300∆femT and USA300∆farER-femT, were visibly more sensitive to oxacillin, with 
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USA300 USA300∆farER USA300∆femT USA300∆farER-femT 
Daptomycin 1 1 1 1 
Vancomycin 2 1 1 1 





Figure 3.4 E-test results for determination of antibiotic sensitivity. Cultures of USA300, 
USA300∆farER, USA300∆femT, and USA300∆farER-femT were spread onto Mueller-Hinton agar 
plates with (A) daptomycin, (B) vancomycin, and (C) oxacillin E-tests. MICs (µg/mL) were read 
directly from the test strip, where the elliptical zone of inhibition intersected with the MIC scale on 
the test strip. 
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3.2 Evaluation of Substrate Redundancy between FemT and FarE 
3.2.1 femT expression is not upregulated in USA300∆farER  
To test for redundancy in substrate efflux between the two RND transporters in S. aureus, the 
expression of femT was evaluated in the USA300∆farER deletion background, to observe whether 
the deletion of farE would cause increased expression of femT. To evaluate femT expression, a 
promoter-reporter expression system was utilized. femT is partially co-transcribed with femX, and 
the genetic organization of femX-femT is conserved among all published annotated staphylococcal 
species (12). Both femX and femT lie on the negative strand of the S. aureus chromosome, and are 
separated by a 116 bp intergenic segment. In addition to the promoter upstream of femX, an 
additional predicted promoter in the intergenic region between femX and femT has been identified 
(163). To evaluate whether the predicted promoter in this region is active, the entire 116 bp 
segment between femX and femT was amplified and cloned into the pGYlux expression vector, 
creating pGYfemT::lux. This construct was then introduced into E. coli DH5α, where luciferase 
activity was monitored at different time points in growth and compared to the activity of the farE 
promoter (Figure 3.5A). Although the femT promoter is not expressing to the same level as the 
farE promotor, the pGYfemT::lux construct is active, and the promoter is driving detectable levels 
of luminescence in E. coli DH5α. 
Once promoter activity was confirmed in E. coli, femT expression was measured in USA300 and 
USA300ΔfarER. Since farE is known to be induced in LA, femT expression was measured in 
USA300ΔfarER in the presence of LA to determine if LA, in the absence of farE, would induce 
expression of femT as a compensatory mechanism. Therefore, USA300 and USA300ΔfarER 
harboring pGYfemT::lux were cultured into triplicate flasks containing either TSB or TSB 
supplemented 20 µM LA (Figure 3.5B). Luminescence measurements suggest that the deletion of 
farER does not cause an increase in femT expression when exposed to TSB alone, or TSB 
supplemented with LA. Although the predicted femT promoter was shown to be highly active when 
monitored in E. coli, expression in S. aureus could only be briefly observed at a low level during 
early exponential growth in USA300 grown in TSB. Time points earlier than 1 hour were not 




Figure 3.5 Assay of femT expression in E. coli, USA300, and USA300∆farER. Growth (OD600; 
open symbols) and relative luminescence units normalized by OD600 (RLU/OD600; closed symbols) 
of (A) E. coli DH5α carrying pGYfarE::lux or pGYfemT::lux, and (B) USA300 and 
USA300∆farER with the pGYfemT::lux reporter vector grown in TSB or TSB with 20 µM LA. 
Each value represents the mean and standard deviation of four separate cultures, and each culture 
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3.2.2 farE exhibits loss of inducible expression in USA300∆femT  
To test whether the deletion of FemT causes a change in farE expression, a promoter gene assay 
was performed measuring farE expression in a USA300∆femT mutant background. To accomplish 
this, the putative promoter of farE was cloned in front of the luciferase operon on the pGYlux 
plasmid and transformed into USA300 and USA300∆femT. Expression of farE was then monitored 
during growth in TSB in the presence and absence of sub-inhibitory (20 µM) concentrations of LA 
and AA (Figure 3.6). As expected from previous experiments, the expression of farE is inducible 
in USA300 when cultured in 20 µM LA and AA, compared to TSB in which farE is not expressed 
(99). Interestingly, inducible expression of farE was lost in the USA300∆femT background when 
cultured in both LA and AA, and expression remained minimal. This is illustrated as a decrease in 
farE expression, measured as RLU/OD600, in USA300∆femT compared to its expression in wild-
type USA300, when grown in LA and AA. The data, therefore, do not support the contention that 
increased expression of farE compensates for inactivation of femT. However, farE expression is 
significantly reduced in USA300∆femT compared to USA300, suggesting perhaps that another 
mechanism is involved. To confirm this phenotype, Western blot analysis of USA300, femT 
mutants, and complemented femT mutants was also performed with specific antibodies generated 
against FarE, as described in the Materials and Methods section. However, attempts of this 














Figure 3.6 farE loses inducible expression in USA300∆femT. Growth (OD600; open symbols) 
and relative luminescence units normalized by OD600 (RLU/OD600; closed symbols) of USA300 
and USA300∆femT harboring the pGYfarE::lux reporter vector. (A) Cultures were grown in TSB 
in the presence and absence of (A) 20 µM linoleic acid (LA); and (B) 20 µM arachidonic acid 
(AA). Each value represents the mean and standard deviation of triplicate cultures, and each culture 
was subjected to quadruplicate luminescence readings at each time point. Significance values of 
RLU/OD600 are shown between (A) USA300 pGYfarE::lux in TSB + LA and USA300∆femT 
pGYfarE::lux in TSB + LA; and (B) USA300 pGYfarE::lux in TSB + AA and USA300∆femT 
pGYfarE::lux in TSB + AA, as determined by unpaired one-tailed Student’s t tests (*, p < 0.05; 
**, p < 0.01; ***, p < 0.001).  

























USA300ΔfemT pGYfarE::lux; TSB + AA
USA300 pGYfarE::lux; TSB

















































3.2.3 USA300∆femT is more susceptible to killing by bactericidal concentration 
of linoleic acid 
To further investigate the reduced expression of farE in USA300∆femT, we investigated the 
hypothesis that the cell wall of USA300∆femT is altered in such a way that does not allow fatty 
acids to enter the cell and induce farE expression. To accomplish this, a bactericidal assay was 
performed to assess bactericidal activity of LA on USA300, USA300∆femT, and USA300∆femT 
containing pALCfemT for complementation. Cultures were grown to exponential phase in TSB 
supplemented with a sub-inhibitory concentration (20 µM) of LA, and then inoculated into flasks 
containing 100 µM LA, a bactericidal concentration. Control curves of USA300 and 
USA300∆femT grown in TSB without LA were not included as both strains grow similarly in TSB, 
which is demonstrated in Figure 1. Interestingly, when grown in bactericidal concentrations of LA, 
the USA300∆femT pALC2073 mutant demonstrated significantly lower survival every hour after 
initial inoculation compared to wild-type USA300 and the USA300∆femT complement (Figure 
3.6). This data shows that mutants that are deficient in femT are more susceptible to killing by 
bactericidal unsaturated free fatty acids, such as LA. Notably, complementation of femT restored 














Figure 3.7 Sensitivity of USA300 and USA300ΔfemT to the bactericidal activity of linoleic 
acid. Cultures of USA300 pALC2073, USA300ΔfemT pALC2073, and USA300ΔfemT 
pALCfemT were exposed to 100 µM LA after growth to mid-exponential phase in TSB–20 µM 
LA. Each data point represents the mean value of quadruplicate cultures. Significant differences 
in viability between USA300 pALC2073 and USA300ΔfemT pALC2073 were determined by 
unpaired one-tailed Student’s t tests (***, p < 0.001). 


























3.2.4 Failure to express farER is responsible for increased sensitivity of femT 
deficient strains to killing by linoleic acid 
Upon determining that USA300ΔfemT had significantly reduced survival in bactericidal 
concentrations of LA compared to wild-type USA300, we wanted to investigate if this phenotype 
was due to loss of farE expression in the femT mutant. To evaluate the role of farE in the increased 
susceptibility of USA300ΔfemT, the mutant strain USA300ΔfarER-femT was utilized, along with 
the femT-complemented version USA300ΔfarER-femT pALCfemT. Bactericidal assays with 
USA300 pALC2073, USA300ΔfarER-femT pALC2073, and USA300ΔfarER-femT pALCfemT 
were carried out under the same conditions tested previously; cells were grown to mid-exponential 
phase in TSB–20 µM LA and then inoculated into flasks containing 100 µM LA.  
As expected, the USA300ΔfarER-femT mutant demonstrated notably lower survival compared to 
wild-type USA300 (Figure 3.7), but when the USA300ΔfarER-femT mutant was complemented 
with pALCfemT, viability was not restored and remained significantly lower than USA300 at all 
time points after initial inoculation. Therefore, USA300ΔfemT and USA300ΔfarER-femT both 
exhibit reduced viability in the bactericidal assay, and viability can be restored by complementing 
with pALCfemT in USA300ΔfemT, but not in USA300ΔfarER-femT. Taken together, these data 
indicate that that farER is not inducible in USA300ΔfemT, leading to reduced viability when 










Figure 3.8 Sensitivity of USA300∆farER-femT to killing by linoleic acid occurs in a farER-
dependent manner. Cultures of USA300 pALC2073, USA300ΔfarER-femT pALC2073, and 
USA300ΔfarER-femT complemented with pALCfemT were exposed to 100 µM LA after growth 
to mid-exponential phase in TSB–20 µM LA. Each data point represents the mean value of 
quadruplicate cultures. Significant differences in viability between USA300 pALC2073 and 
USA300ΔfarER-femT pALCfemT were determined by unpaired one-tailed Student’s t tests (*, p 
< 0.05; **, p < 0.01; ***, p < 0.001).  



























The emergence of MRSA has become a significant disease burden worldwide, and S. aureus 
USA300 is a prominent strain of CA-MRSA responsible for severe invasive infections in humans. 
However, to colonize successfully and establish infection, USA300 must overcome host defense 
mechanisms, including antimicrobial unsaturated free fatty acids that are encountered on the skin 
and in soft tissue abscesses. A contributing factor known to play a vital role in the intrinsic defense 
mechanisms of bacterial pathogens is the RND superfamily of efflux pumps, which are ubiquitous 
among bacteria. In addition to their diverse roles in drug resistance, virulence, and promoting key 
physiological processes, RND efflux pumps in many bacterial pathogens are required for causing 
infection. Although the structure and functions of RND transporters are being extensively studied 
in both Gram negative and Gram positive bacteria, many outstanding questions remain regarding 
the characterization of this family of transporters in S. aureus. 
In addition to our own work, which identifies mild phenotypes of the RND transporter mutant 
USA300ΔfemT in conditions that impose stress on the cell wall, Quiblier et al. using a different 
approach with S. aureus Newman demonstrated that FemT (SA2056) interacted with some of the 
FemABX factors and the PBPs, suggesting a subsidiary role in peptidoglycan synthesis (163). 
Despite the extensively characterized roles of RND family efflux pumps as mediators of multidrug 
resistance, we proposed that the function of FemT is to contribute to the basic biology of S. aureus, 
namely to cell wall synthesis. This is consistent with the role of RND transporters in M. 
tuberculosis, where the primary role of most MmpL RND proteins appears to be the transport of 
lipids to be incorporated on the cell envelope (164). To elucidate the role of FemT in S. aureus 
USA300, analysis of the markerless femT knock-out mutant was extended to various growth and 
stress conditions. 
First, once femT deletions in USA300 and USA300ΔfarER were created, growth of the mutants 
was analyzed in four different types of media. Typically, a range of different media are used for 
cultivating S. aureus in studies from different laboratories; these are mostly complex media such 
as TSB, BHI broth, MHB, and LB broth (165). Evaluating the growth of mutants in different media 
is important, as previous research has indicated that different media have major effects on the 
expression of selected target virulence and regulatory genes (165, 166). Interestingly, the femT 
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deletion mutant grew at a slightly faster rate during mid-exponential growth compared to wild-
type in MHB. In comparison, all strains grew at approximately equal rates in the other media 
tested. MHB is composed of beef extract powder (2 g/L), acid digest of casein (17.5 g/L), and 
soluble starch (1.5 g/L). Thus, by far the major component of this medium is acid digest of casein, 
and this is expected to be high in free amino acids, and may have an impact on bacterial cell 
properties. Indeed, Sen et al. have demonstrated that the balance of branched-chain fatty acids and 
straight-chain fatty acids in the membranes of USA300 strains JE2 and SH1000 was affected 
considerably by growth in different media; in particular, MHB resulted in high branched-chain 
and low straight-chain fatty acids, whereas growth in TSB and BHI broth led to a reduction in 
branched-chain and an increase in straight-chain fatty acids (167). In addition, the membranes of 
MHB- and serum-grown cells were significantly less fluid compared to cells grown in other media, 
possibly due to the higher carotenoid contents of cells grown in MHB, which rigidifies the 
membrane (167). Taken together, these altered membrane characteristics of MHB-grown cells 
suggest that the ratio of components in MHB differ from TSB, BHI broth, and RPMI broth in such 
a way that enhances growth of USA300ΔfemT in MHB, which perhaps is attributable to membrane 
perturbations of cells grown in this media. Glucose, for example, is absent in MHB, but present in 
TSB, BHI broth, and RPMI broth, and may possibly account for this phenotype. When S. aureus 
cultures are grown in media lacking glucose, cells are forced to utilize secondary sources of carbon, 
such as amino acids (168). Under these conditions, perhaps the femT-deficient mutant is better able 
to accommodate the metabolic changes, and thus, can grow at a faster rate compared to wild-type. 
Growing these cultures in TSB without glucose, or in MHB supplemented with glucose, would 
prove valuable to examine the role of glucose in this phenotype. Interestingly, Huang et al. found 
the opposite effect, where the deletion of the RND pump smeIJK in Stenotrophomonas maltophilia 
mediated growth retardation in MHB, which was reversible when the cultured environment was 
changed from MHB to LB broth (169). The mechanism behind the growth perturbation remains 
as a future area of study; for example, it may be useful to examine the membrane properties of 
USA300ΔfemT when grown in each media. 
Hypothesizing that FemT plays a role in cell wall synthesis, it is noteworthy that the femT mutant 
was more susceptible to lysis with lysostaphin compared to wild type USA300, as this phenotype 
may suggest that FemT contributes to biosynthetic pathways for cell wall assembly. Lysostaphin 
is a endopeptidase produced by Staphylococcus simulans biovar staphylolyticus and lyses 
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staphylococcal cells by hydrolyzing the Gly5 bridges that cross-link the peptidoglycan of several 
members of this genus, including S. aureus (170). Although mutants defective in either the femA 
or femB genes are more resistant to lysostaphin due to shortened Gly5 interpeptides, Morikawa et 
al. using S. aureus N315 showed that cell wall thickness also plays important roles in lysostaphin 
sensitivity, whereby cells with thinner envelopes demonstrated increased sensitivity to lysostaphin 
(156). Based on these findings, it is possible that the glycine-glycine bond of the crossbridge is not 
altered in the femT mutant, but it may be possible that the cell wall of USA300ΔfemT is marginally 
thinner than wild-type, contributing to increased lysostaphin sensitivity. This alleged phenotype 
of the mutant could also explain its increased sensitivity to antibiotics that target the cell wall.  
Research by Cui and colleagues demonstrated a significant statistical correlation between the cell 
wall thickness of 48 S. aureus strains and vancomycin MICs; specifically, the thickening of the 
cell wall is closely associated with the mechanism of vancomycin resistance in resistant strains 
(171). In this mechanism proposed by several researchers, trapping of vancomycin molecules in 
the cell wall peptidoglycan would be the essential contributor; the thicker the cell wall, the more 
vancomycin molecules trapped within the cell wall, thus allowing fewer molecules to reach the 
cytoplasmic membrane where the real functional targets of vancomycin are present (171–174). 
Vancomycin binds to the stem peptide of the membrane-anchored lipid II precursor at its dipeptide 
moiety, Lys-D-Ala-D-Ala residue, and thus prevents the precursor from being incorporated into 
the nascent peptidoglycan chain (160–162). In addition, a thicker peptidoglycan layer also 
significantly reduces the time that vancomycin completely inhibits peptidoglycan synthesis. This 
theory holds true of glycopeptide antibiotics, including vancomycin and teicoplanin, and also of 
β-lactams, including imipenem and oxacillin, although to a lesser extent (171). Conversely, the 
opposite could hold true for strains with a thinner cell wall, as a thinner peptidoglycan layer may 
allow vancomycin to more readily reach the cytoplasmic membrane and completely inhibit 
peptidoglycan synthesis. In E. coli, cells with reduced peptidoglycan content were more sensitive 
to β-lactam antibiotics, including penicillin and other damaging agents, and cells withstood this 
drastic reduction in the amount of peptidoglycan without detectable alterations in their 
morphology, growth, division, and viability in the stationary phase (175). Based on these findings, 
if the cell wall of USA300ΔfemT is slightly thinner than wild-type, it seems likely that this would 
contribute to the increased sensitivity of the mutant to both vancomycin and oxacillin, without 
affecting growth in culture. 
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Additionally, while the femT mutant showed an increased sensitivity to lysostaphin, vancomycin 
and oxacillin, the deletion mutant was not found to be differentially affected by lysozyme 
compared to wild-type. Lysozyme is one of the most important enzymes of the innate immune 
system, as it is a component of neutrophil granules, the major secretory product of macrophages, 
and it is also found in mammalian secretions and tissues (176, 177). Although lysozyme 
preferentially hydrolyzes the β-1,4-glycosidic linkages between MurNAc and GlcNAc, it does not 
recognize peptidoglycan modified with O-acetyl groups, which enables pathogenic bacteria such 
as S. aureus to overcome this innate defense mechanism (178). S. aureus acetylates its cell wall at 
the C-6 position of MurNAc, producing the 2,6-N,O-diacetylmuramic acid derivative (158). This 
modification acts as a steric hindrance and inhibits the binding of the lysozyme to the 
polysaccharide substrate. Bera et al. have previously provided evidence that the O-acetylation of 
peptidoglycan correlates with the observed high lysozyme resistance by S. aureus, which is 
mediated by a peptidoglycan-specific, membrane-bound O-acetyltransferase (OatA) (158). In this 
study, researchers show that OatA is widespread among pathogenic staphylococci, whereas 
nonpathogenic staphylococci are lysozyme sensitive and possess no O-acetylated peptidoglycan 
(158). Therefore, to investigate whether FemT played a role in the acetylation of peptidoglycan, 
we tested the growth of the femT mutant compared to wild-type USA300 when exposed to 
lysozyme. However, both appeared to be equally resistant to lysozyme, which suggests that 
peptidoglycan acetylation was not altered in USA300∆femT.  
Although a striking phenotype of USA300∆femT was not found upon exposure to several of the 
conditions tested, the mutant was identified to grow faster in MHB, and is slightly more sensitive 
to vancomycin, oxacillin, and lysostaphin compared to wild-type; however, femT was not required 
for S. aureus growth or stress tolerance when grown in culture and upon exposure to lysozyme and 
daptomycin. However, the increased sensitivity of USA300∆femT to lysostaphin and cell wall-
targeting antibiotics may implicate an accessory role for FemT in cell wall biosynthesis. It is 
possible that FemT and other proteins share redundancy in substrate efflux, as cell wall synthesis 
genes are especially redundant, and that deletion of femT alone does not impair S. aureus 
sufficiently to produce a striking phenotype. Interestingly, S. aureus can survive with minimal 
peptidoglycan synthesis genes, and Reed et al. demonstrated that as many as seven of the nine 
genes encoding synthesis enzymes can be deleted without affecting normal growth or cell 
morphology; however, virulence and antibiotic resistance are sacrificed in these mutants (179). 
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Therefore, future research should be directed at examining the virulence of USA300∆femT and 
USA300∆farER-femT in a murine colonization model to extend the evaluation of FemT in vivo.  
A common feature of bacterial pathogens encoding multiple RND pumps is that their functions in 
substrate efflux tend to be redundant. For example, P. aeruginosa has more than ten RND family 
transporters, of which nine transport multiple, often the same, antibiotic substrates (180). Due to 
the redundancy of RND pumps, potential exists for the loss of certain pump components to be 
compensated by increased expression of a homologous pump that could accomplish, at least to 
some extent, the same function. For example, Eaves et al. demonstrated that when acrB or acrF 
of Salmonella was inactivated, the expression of acrD increased (181). Similarly, Blair et al. have 
shown that the expression of all RND efflux pump genes in S. typhimurium can be altered when 
single or multiple acr genes are inactivated (182). Comparably, RND transporters MmpL4 and 
MmpL5 in M. tuberculosis have redundant functions in siderophore export, whereby inactivation 
of either pump increases expression of the other, but a double MmpL4/5 mutant is lethal (183). 
Since these transporters efflux a wide range of substrates, inactivation of one transporter may alter 
the balance of metabolites in the cell, and expression of other RND transporters may be adjusted 
accordingly. Therefore, the redundancy feature of RND transporters contributes to bacterial 
resilience in many different growth conditions. 
Interestingly, when testing for substrate redundancy between FemT and the fatty acid resistance 
transporter, FarE, our results show that femT expression via the predicted promoter is unchanged 
in the farER-deletion mutant. Conversely, we observed a loss of inducible farE expression in the 
femT-deletion mutant. In wild-type, farE is only expressed in TSB supplemented with LA and AA, 
but in USA300∆femT, farE is not expressed under these conditions. The data, therefore, do not 
support the contention that increased expression of farE compensates for inactivation of femT. 
These results suggest that perhaps another mechanism is involved, or that the cell of 
USA300∆femT is altered in such a way that does not allow LA or AA to induce farE expression. 
One simple solution could be that FemT acts as both an efflux pump and a portal of entry for 
certain molecules, such as fatty acids. If this was the case, it would explain why farE loses 
inducible expression in the femT deletion mutant, as fatty acids are unable to enter the cell and 
induce expression. It would also explain why the USA300ΔfemT mutant is more susceptible to LA 
in a bactericidal assay, and when introducing femT back in trans, viability is restored. However, 
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this idea still raises some questions as to specificity of fatty acid entry over other metabolites, and 
the mechanism by which this process would occur. 
Although the mechanism by which farE is induced by LA and AA remains to be determined, it is 
probable that exogenous fatty acids must enter the cell to induce farE expression. Therefore, it 
seems likely that the femT mutant is altered in such a way that does not allow entry of fatty acids. 
Alternatively, it is possible that the regulation of farE requires specific forms of phosphorylated 
fatty acids, and not free fatty acids, to promote farE expression. As discovered by Parsons et al., 
fatty acid kinase A (FakA) is an integral part of the fatty acid kinases, which carries out the first 
step of incorporating fatty acids into the cell membrane by phosphorylating them into acyl-PO4 
(184). If farE does indeed require the phosphorylated forms of fatty acids, perhaps the fatty acid 
kinase pathway is altered in USA300∆femT, and is therefore unable to induce expression of farE. 
First, an altered cell membrane will be considered. 
Extracellular fatty acids translocate to the inner leaflet of the cell membrane by spontaneous 
flipping via the membrane pH gradient, and once inside the cell, they are phosphorylated by the 
fatty acid kinases (184, 185). Since fatty acids must insert into the membrane to exert their effects, 
the ability of some bacteria to change their cell surface hydrophobicity may explain why certain 
strains of the same species differ with respect to their susceptibility to antimicrobial fatty acids 
(97, 186). For example, the femT mutant may contain fewer proteins in its cell membrane, which 
makes the cell surface less charged and more hydrophobic. Thus, free fatty acids are more attracted 
to the cell and are more likely to insert into the membrane, exerting their toxic effects (97, 186, 
187). This is consistent with our observation that USA300∆femT is more susceptible to killing by 
bactericidal concentrations of LA compared to wild-type. An example of such a component in the 
membrane that contributes to this phenotype is the membrane-located carotenoids. Carotenoids 
are antioxidants that also stabilize the cell membrane by decreasing fluidity and, if they are 
increased in number, their presence may counteract the effects of free fatty acid degradation 
products or fatty acid-induced increases in membrane fluidity (188). Indeed, strains of S. aureus 
containing high levels of carotenoids are less susceptible to the antibacterial effects of unsaturated 
fatty acids than strains with lower quantities of carotenoids in their membranes (95, 188). 
Therefore, it seems likely that if S. aureus strains such as USA300∆femT contain reduced amounts 
of membrane carotenoids or other large membrane proteins, these cells would be more susceptible 
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to fatty acids. Interestingly, in some species, RND family transporters are thought to be utilized to 
replace fatty acids from membranes as part of maintaining homeostasis (189). Although this 
mechanism is not currently understood, this phenomenon, along with a decrease in other 
membrane proteins, could explain why, when femT is deleted, the membrane may be more fluid 
and more susceptible to the insertion of fatty acids. In addition, a more fluid membrane of femT-
deficient cells could explain its enhanced growth in MHB, as this media promotes a higher 
proportion of branched-chain fatty acids and carotenoids in the cell membrane, which may aid the 
growth of USA300∆femT compared to cells with a naturally more rigid membrane.  
Increased susceptibility of the femT mutant to LA may also be due to the proposed thinner cell 
wall. In addition to altered membrane properties of the cell, differential susceptibility of bacterial 
species to the action of fatty acids is also likely to be due to the ability of exogenous fatty acids to 
permeate the cell wall, which will enable access to the sites of action on the membrane (187). 
Interestingly, S. aureus appears to upregulate the expression of genes encoding cell wall synthesis 
proteins upon exposure to unsaturated free fatty acids, a strategy that serves as a protective 
measure, as a thicker cell wall makes it more difficult for fatty acids to penetrate and exert their 
antibacterial effects at the membrane (185). An altered cell membrane and/or cell wall provides a 
reasonable interpretation of the increased susceptibility of USA300∆femT to LA. However, it does 
not explain the loss of inducible farE expression. Before a definitive explanation for this phenotype 
can be determined, the mechanism by which farE is induced by LA and AA needs to be 
investigated. One possible theory that will be discussed further is the disruption of the fatty acid 
kinase pathway.  
In the USA300 genome, farE is divergently transcribed with farR, a regulator of fatty acid 
resistance, and expression of farE is induced in a farR-dependent mechanism in response to 
exogenous fatty acids (99). It is believed that FarR may function as a repressor of farE in the 
absence of inducer, and in the presence of exogenous fatty acids, may serve to promote expression 
of farE (99). While farE was found to be induced by exposure to fatty acids, it is unknown whether 
the induction requires free fatty acids or if it requires specific forms of phosphorylated acyl-PO4 
fatty acids that have been incorporated into S. aureus by the fatty acid kinases. Interestingly, when 
farE expression was measured in a fakA-deficient mutant (USA300ΔfakA), farE expression, in 
media alone and media supplemented with LA, was significantly reduced compared to its 
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expression in USA300 grown in LA (147). Moreover, farE loses its inducible expression in LA in 
the fakA mutant. These results are very similar to the expression of farE in the femT-deficient 
mutant, where farE loses its inducible expression in both LA and AA. Taken together, these results 
are consistent with the notion that the regulation of farE requires specific forms of acyl-PO4 and 
not free fatty acids to promote farE expression. Therefore, if the fatty acid kinase pathway was 
disrupted in the USA300ΔfemT mutant, it would explain the lack of change in farE expression 
between USA300ΔfemT grown in TSB or in fatty acids. Although the mechanism is not currently 
understood, what is known is that farE expression is significantly reduced in femT deficient 
mutants. This is consistent with the observation that USA300ΔfemT and USA300ΔfarER-femT 
both exhibit reduced viability in the bactericidal assay, and viability can be restored by 
complementing with pALCfemT in USA300ΔfemT, but not in USA300ΔfarER-femT. To confirm 
this phenotype is due to loss of farE, complementing USA300ΔfarER-femT with pALCfarE would 
prove valuable. Identifying why fatty acid kinase activity might be altered in USA300ΔfemT and 
identifying specific regulation of farE remains a future area of study. Since the inactivation of the 
fatty acid kinases severely attenuates virulence factor production in S. aureus, it would prove 
highly valuable to examine the virulence of USA300ΔfemT (184).  
In summary, we have examined the involvement of FemT in cell wall synthesis and the relationship 
between FemT and FarE transporters in S. aureus resistance to unsaturated free fatty acids. Results 
of this study implicate a possible involvement of FemT in cell wall biosynthesis, and identified a 
multifactorial relationship between RND transporters FemT and FarE. Notably, farE loses 
inducible expression in mutants lacking FemT. The USA300ΔfemT mutant was also significantly 
more susceptible to bactericidal concentrations of unsaturated free fatty acids compared to wild-
type. Cumulatively, these findings represent the first description of both RND efflux systems 
operating in S. aureus. Detailed evaluation of RND transporter function will provide novel insight 
into the biology of staphylococci and further our understanding of this ubiquitous family of 
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